Skip to content

NF-kB

HTLV-1 Tax induces PINK1-PRKN/parkin-dependent mitophagy to mitigate activation of the CGAS-STING1 pathway

The finding

This paper shows that the HTLV-1 Tax protein hijacks the PINK1Parkin mitophagy pathway to clear damaged mitochondria and suppress cGASSTING activation. Tax induces mitochondrial ROS and membrane-potential disruption, then recruits the autophagy receptors CALCOCO2/NDP52 and SQSTM1/p62 to drive mitophagic clearance. Critically, Tax requires PRKN to limit cGAS-STING1 activation and type I interferon induction — a viral immune-evasion strategy that also sustains viral gene expression and cell survival.

Where it fits

This speaks directly to Loop A (IFN-I/JAK-STAT) and the mitochondrial quality-control node that the SAMHD1 A565T model predicts is corrupted. In the SAMHD1 model, ISG15 ISGylates MFN1/2 and BECN1, blocking mitophagy so damaged mitochondria persist and keep leaking mtDNA to cGAS-STING. This paper provides the mechanistic counterexample: when PINK1-Parkin mitophagy works, it clears damaged mitochondria and prevents cGAS-STING activation. That is exactly the clearance step the SAMHD1 model predicts is disabled — and it confirms that mitophagy is a genuine checkpoint for tonic IFN-I, not just a downstream consequence of mitochondrial stress.

The paper also reinforces the model's claim that mtDNA release is the key ligand for cGAS: Tax's suppression of IFN depends on removing the mitochondria that would otherwise release mtDNA, not on directly inhibiting cGAS itself.

Caveats

  • This is a viral system (HTLV-1 Tax), not a SAMHD1 model — the relevance is mechanistic analogy, not direct demonstration in A565T cells.
  • The experiments use overexpression and viral-transformed cell lines, not primary cells from SAMHD1 patients; the mitophagy-cGAS link is established here, but the specific failure mode in A565T remains inferred.
  • The paper shows Tax requires PRKN to suppress cGAS-STING, but does not address whether partial loss of mitophagy (as predicted in SAMHD1 A565T) produces a graded, smouldering IFN response versus an all-or-nothing switch.

What to watch

Does restoring PINK1-Parkin activity in SAMHD1 A565T cells — for example, by blocking ISG15-mediated inhibition of mitophagy — phenocopy Tax's suppression of cGAS-STING? That would be the direct test of whether the model's Loop A is truly self-sustaining via mitophagy blockade.


Source: HTLV-1 Tax induces PINK1-PRKN/parkin-dependent mitophagy to mitigate activation of the CGAS-STING1 pathway — 2026.

SAMHD1 Research Digest — 2026-08-19

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 13 papers evaluated | 2 high-relevance (≥7) | 8 medium (5–6) | 3 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

A genome-wide map of the genetic network in monocytes that regulates type I interferon induction by the cGAS-STING pathway. (from functional genomics/CRISPR screening)
Thomsen Emil Aagaard; Zhao Jian; Narita Ryo; Davis Luther J; Olagnier David — Science signaling 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, NF-kB-IKK

This CRISPR screen maps genetic regulators of cGAS-STING-driven IFNB1 induction in monocytes, directly relevant to the BLUE pathway (cGAS-STING-IRF3-IFN-I) implicated in SAMHD1 haploinsufficiency and identifies novel druggable nodes (e.g., TBK1/HDAC3) for interferonopathy therapy.
DOI: 10.1126/scisignal.adx3808

Type I Interferonopathies in the Differential Diagnosis of Vasculitis: A Comprehensive Review. (from Rheumatology/vasculitis)
Gürbüz Nida; Ismayilova Shams; Ahmadova Gulnar; Çiftçi Rena; Aksu Güzide — Journal of visualized experiments : JoVE 2026
Score: 7/10 | Pathways: cGAS-STING, JAK-STAT, AGS-spectrum, treatment-target, clinical-phenotype

This review directly covers SAMHD1 as a monogenic type I interferonopathy gene within the cGAS-STING/JAK-STAT axis, discusses interferon gene signature diagnostics and JAK inhibitor therapy, and links IFN-I dysregulation to vasculitic/autoimmune phenotypes relevant to the family's rheumatologic and autoimmune manifestations, though it does not focus specifically on SAMHD1 A565T.
DOI: 10.3791/71286

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Atractylodes macrocephala Koidz. Polysaccharides Alleviate Liver Fibrosis in Association With Suppression of cGAS-STING Signaling and Mitochondrial Apoptosis. (from Hepatology/ethnopharmacology)
Wu Jiali; Hu Xianzhe; Liu Jing; Peng Hongye; Chen Bo — Journal of ethnopharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, treatment-target

Demonstrates a natural compound suppressing cGAS-STING-NLRP3 signaling and mitochondrial danger signaling to reduce liver fibrosis, directly relevant to the BLUE/Loop A axis and NF-κB-NLRP3 priming mechanism central to the disease model, though it is in a non-SAMHD1 liver fibrosis context.
DOI: 10.1016/j.jep.2026.122313

The mitophagy-inflammasome axis: a shared pathological hub in Alzheimer's and Parkinson's diseases. (from neurology/neurodegeneration)
Long Wei; Yuan Mengqin; Wang Sirui; Tan Xinyue; Gao Li-Chen — Translational neurodegeneration 2026
Score: 6/10 | Pathways: NLRP3, mito-ROS-NF-kB, treatment-target

Reviews mitophagy-inflammasome crosstalk (ROS/mtDNA-driven NLRP3 activation and mitophagy suppression) that parallels the PURPLE/RED/Loop B mechanisms in the SAMHD1 syndrome, though focused on neurodegeneration rather than SAMHD1 directly.
DOI: 10.1186/s40035-026-00578-w

PPARα deficiency exacerbates atherosclerosis progressing through enhancing pTh17 cells-macrophage crosstalk. (from Cardiology/vascular immunology)
Ren Tong; Jiang Xilin; Wu Jianfeng; Yan Changsheng; Peng Lu — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, other

Demonstrates mtDNA leakage activating the cGAS-STING axis to drive pathogenic immune cell differentiation and inflammation in atherosclerosis, mechanistically parallel to the BLUE loop mitochondrial-to-cGAS-STING signaling in SAMHD1 haploinsufficiency though in a distinct disease context.
DOI: 10.1016/j.ejphar.2026.179247

Long-chain chlorinated paraffins exposure induces premature ovarian failure by disrupting the balance of mitochondrial fission. (from Reproductive toxicology/gynecology)
Xu Chenhui; Deng Haochu; Tian Xue; Ma Shuang; Kong Yuebing — 2026
Score: 6/10 | Pathways: cGAS-STING, other

Demonstrates a toxicant-induced mitochondrial fission-mtDNA leakage-cGAS-STING-senescence axis mechanistically analogous to the disease's BLUE pathway (VDAC1/mtDNA/cGAS-STING) though in a reproductive rather than immune context.
DOI: 10.1007/s11010-026-05696-7

Minimally invasive extracorporeal circulation protects against postoperative pulmonary endothelial injury in elderly cardiac surgery via suppressing the C5a-mtDNA-cGAS-STING axis: a mechanistic randomized controlled trial. (from Cardiothoracic surgery / perioperative critical care)
Zhao Yun; Wang Jiaxing; Yang Zhaohua; Ma Wenrui; Wang Chunsheng — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, other

Demonstrates mtDNA release triggering cGAS-STING activation and endothelial injury in a surgical inflammation model, mechanistically parallel to the BLUE/mitochondrial-cGAS-STING axis in SAMHD1 haploinsufficiency though not disease-specific.
DOI: 10.1016/j.intimp.2026.117281

Engineered Exosome-Mediated FIH-1 Delivery for Targeted Therapy of Hyperuricemic Nephropathy by Inhibiting NF-κB/NLRP3 Inflammasome Signaling and Restoring Autophagic Homeostasis. (from Nephrology/regenerative medicine (exosome-based nanotherapeutics))
Xiao Ting; Liu Yu; He Zhe; Yang Ailing; Li Jing — Advanced healthcare materials 2026
Score: 6/10 | Pathways: urate-NLRP3, NF-kB-NLRP3-priming, NLRP3, treatment-target, mTOR-lysosomal

Demonstrates uric acid/MSU-driven NF-κB/NLRP3 activation and autophagy restoration in nephropathy, directly paralleling the GOLD gout/urate-NLRP3 axis and NF-κB priming crosstalk relevant to SAMHD1-driven interferon-mitochondrial disease, though it is a nephrology/regenerative-medicine context without SAMHD1 linkage.
DOI: 10.1002/adhm.71602

Mitochondrial Dysfunction as a Central Hub of Aging: From Molecular Cascades to Inter-Organ Communication Networks. (from Gerontology/aging biology)
Han Chaodong; Zhang Zilian; Song Yafeng — Gerontology 2026
Score: 5/10 | Pathways: cGAS-STING, NLRP3, mito-ROS-NF-kB, treatment-target

This general aging review covers cGAS-STING/NLRP3-driven inflammation from mitochondrial dysfunction and mitokine signaling, mechanistically overlapping with the Purple/Blue/Gold loops but without any SAMHD1, dNTP, or disease-specific data.
DOI: 10.1159/000553430

Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. (from gene therapy / synthetic biology engineering)
Jung Hyuncheol; Devant Pascal; Ching Carter; Ota Mineto; Dann Emma — Nature biotechnology 2026
Score: 5/10 | Pathways: gene-therapy-delivery, treatment-target

This paper describes a VLP-based CRISPR/base-editing delivery platform for primary human myeloid cells, relevant as a potential future correction/delivery strategy for SAMHD1 immune-cell mutations but not directly addressing SAMHD1 or its interferon-mitochondrial mechanism.
DOI: 10.1038/s41587-026-03258-2

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

Lactate oxidase-engineered manganese layered double hydroxide nanoplatform amplifies cGAS-STING activation for tumor immunotherapy. (from Nanomedicine/oncology)
Cai Feng; Jiang Dengsheng; Geng Mingzhe; Xu Hongbo; Song Shilong — 2026
Score: 4/10 | Pathways: cGAS-STING, treatment-target

Describes cGAS-STING activation via mtDNA release and oxidative mitochondrial damage in a tumor immunotherapy nanoplatform, mechanistically touching the pathway but in an oncology-engineering context unrelated to SAMHD1 haploinsufficiency or its downstream family phenotypes.
DOI: 10.1016/j.ijbiomac.2026.153862

Astragaloside IV Protects against PM2.5-Induced Spermatocyte Injury via the cGAS-STING/Nrf2/HMOX1 Axis. (from reproductive toxicology/andrology)
Jin Jin; Zhang Congxue — Reproductive toxicology (Elmsford, N.Y.) 2026
Score: 4/10 | Pathways: cGAS-STING, treatment-target

This paper demonstrates cGAS-STING pathway activation and pharmacologic suppression (via AS-IV) in a PM2.5-induced spermatocyte toxicity model, showing mechanistic overlap with the interferon arm of the syndrome but in an unrelated reproductive toxicology context without SAMHD1 or mitochondrial dNTP linkage.
DOI: 10.1016/j.reprotox.2026.109328

Sex-sikpecific associations between serum uric acid and chronic rhinosinusitis: a retrospective case-control study. (from Otolaryngology/Rheumatology (uric acid metabolism))
Zhou Jiaxin; Wu Fan; Wang Chang; Kong Haobo; Liu Yehai — Frontiers in allergy 2026
Score: 3/10 | Pathways: urate-NLRP3

Paper links serum uric acid to chronic rhinosinusitis via sex-specific effects, touching the GOLD pathway (uric acid/MSU-NLRP3 axis) only tangentially without any SAMHD1, interferon, or mitochondrial mechanism.
DOI: 10.3389/falgy.2026.1870468


Pathway Coverage This Week

  • treatment-target: 11 papers
  • cGAS-STING: 9 papers
  • NLRP3: 4 papers
  • other: 3 papers
  • mito-ROS-NF-kB: 2 papers
  • urate-NLRP3: 2 papers
  • NF-kB-IKK: 1 papers
  • JAK-STAT: 1 papers
  • AGS-spectrum: 1 papers
  • clinical-phenotype: 1 papers
  • NF-kB-NLRP3-priming: 1 papers
  • mTOR-lysosomal: 1 papers
  • gene-therapy-delivery: 1 papers

SAMHD1 Research Digest — 2026-08-16

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 29 papers evaluated | 2 high-relevance (≥7) | 14 medium (5–6) | 13 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Simulated Microgravity Induced Mesenchymal Stem Cell Senescence via the Activation of Cytosolic mtDNA-cGAS-STING Axis. (from Aerospace/regenerative medicine (stem cell biology under microgravity))
Huang Lei; Huang Rui; Lv Wenjun; Li Zimeng; Tu Yun — 2026
Score: 7/10 | Pathways: cGAS-STING, VDAC1, treatment-target

This paper directly demonstrates the BAK/BAX-VDAC-mediated mtDNA leakage → cGAS-STING activation axis (BLUE stream) driving cellular senescence, mechanistically paralleling the core interferon-mitochondrial pathway implicated in the SAMHD1 A565T syndrome, with STING inhibition (C176) shown as a viable therapeutic strategy.
DOI: 10.1002/jcp.70220

Taulipro rescues mitochondrial dysfunction and inhibits cGAS–STING neuroinflammation in Aβ-driven Alzheimer's disease models (from Neurology/Neurodegeneration (Alzheimer's disease))
Tian Mao; Zhu Xiuping; Lei Zhifeng; Lu Yongheng; Mo Lin — 2026
Score: 7/10 | Pathways: cGAS-STING, POLG-mtDNA, NF-kB-IKK, treatment-target

This paper demonstrates mtDNA leakage-driven cGAS-STING-TBK1-IRF3-NFκB neuroinflammation as an upstream pathogenic mechanism directly analogous to the BLUE/RED loops in the SAMHD1 interferon-mitochondrial syndrome, with a novel therapeutic (Taulipro) targeting the mtDNA leakage step relevant to future treatment strategies.
DOI: 10.21203/rs.3.rs-10416296/v1

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Honokiol targets cyclophilin D and blocks mitochondrial DNA release to inhibit microglial NLRP3 inflammasome activation and alleviate neurodegeneration in Parkinson's disease models. (from Neurology/neurodegeneration (Parkinson's disease) and natural product pharmacology)
Gan Qinglin; Xian Yingtong; Zhou Ting; Fu Xiaolong; Gou Shiyi — Chemico-biological interactions 2026
Score: 6/10 | Pathways: NLRP3, mito-ROS-NF-kB, treatment-target

This paper demonstrates mtDNA release triggering NLRP3 inflammasome activation via mitochondrial permeability transition (CypD), mechanistically parallel to the VDAC1/mtDNA-NLRP3 axis central to the SAMHD1 syndrome, and offers a small-molecule therapeutic (honokiol) strategy relevant to inflammasome modulation.
DOI: 10.1016/j.cbi.2026.112305

Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis. (from Hepatology)
Peng Qian; Wang Sujuan; Zhang Yufeng; Luo Yangjun; Lan Beiwu — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, clinical-phenotype

This paper demonstrates mitochondrial fragmentation (via OPA1 splicing dysregulation) leading to cytosolic mtDNA release and cGAS-STING activation driving fibrotic inflammation, mechanistically paralleling the BLUE loop (VDAC1/mtDNA-cGAS-STING) in the SAMHD1 profile despite a different upstream trigger and hepatic rather than systemic context.
DOI: 10.1097/hep.0000000000001836

TANK-binding kinase 1 (TBK1): unexpected cell type-specific immune regulation beyond antiviral type I interferon signaling. (from virology/vaccinology)
Almeida Mariana S; Bezbradica Jelena S; Coban Cevayir — Current opinion in virology 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target

TBK1 is the key non-canonical IKK kinase (IKKe/TBK1 partner) linking cGAS-STING/IRF3 to both IFN-I and NF-kB signaling, and this review's discussion of cell-type-specific TBK1 functions and pharmacological inhibition is directly relevant to the STING-IRF3-NFkB crosstalk axis and potential therapeutic targeting in the interferonopathy mechanism.
DOI: 10.1016/j.coviro.2026.101545

Structural and single-molecule insights into the core human mitochondrial DNA replisome. (from structural biology/biochemistry)
Plaza-G A Ismael; Miguez-Amil Samuel; Hayes Allison M; Ciesielski Grzegorz L; Fe — The Biochemical journal 2026
Score: 6/10 | Pathways: POLG-mtDNA, mito-dNTP-transport

Detailed structural insight into the Polγ/Twinkle/mtSSB replisome is directly relevant to the POLG-stalling and mtDNA replication stress steps implicated in the PURPLE pathway of this syndrome's mechanism.
DOI: 10.1042/BCJ20260373

Emerging microbiome–mitochondria crosstalk in host defense and infectious diseases: mechanistic insights into NLRP3 inflammasome activation and mtDNA-mediated immunomodulation (from Microbiology/gastroenterology (gut microbiome-mitochondria crosstalk))
Xinxing Lu; Wenbin Sun; Daowei Zhang; Bin Hou; Huiyu Tai — Frontiers in Cellular and Infection Microbiology 2026
Score: 6/10 | Pathways: NLRP3, cGAS-STING, ISG15-mitophagy, mito-ROS-NF-kB, other

Reviews mtDNA-driven cGAS-STING/NLRP3 activation and PINK1/Parkin mitophagy as general mechanisms overlapping core disease pathways, though framed via gut microbiome rather than SAMHD1-specific dysregulation.
DOI: 10.3389/fcimb.2026.1866924

cGAS-STING as a Neuroimmune Traffic Molecule: Unraveling Pathogenic Mechanisms and Therapeutic Potential in Neurological Disorders. (from Neurology/Neuroimmunology)
Rahim Abdul; Zubair Shaik Mahammad; Ahamed Mustak; Das Soumi; Patel Royal — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, clinical-phenotype

This review details cGAS-STING/mtDNA-driven neuroinflammation (Loop A) and its therapeutic targeting, relevant to the AuDHD/neurological phenotype in the SAMHD1 family though not SAMHD1-specific.
DOI: 10.1007/s11481-026-10307-9

Subacute ruminal acidosis induces colonic inflammation and barrier damage via cGAS-STING pathway in Hu sheep fed a high-grain diet. (from Veterinary gastroenterology/animal science)
Meng Meijuan; Shi Xiaoli; Tu Yuanlu; Bai Yunfeng; Chang Guangjun — 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target

This paper demonstrates mtDNA release triggering cGAS-STING/NF-κB pathway activation and downstream inflammation, mechanistically paralleling the BLUE loop (VDAC1/mtDNA/cGAS-STING) in the SAMHD1 syndrome model despite being an unrelated ruminant/agricultural species and disease context.
DOI: 10.1016/j.jnutbio.2026.110483

Vilazodone inhibits NLRP3 inflammasome assembly by targeting the NACHT domain and alleviates inflammatory disease. (from psychiatry/pharmacology (antidepressant drug repurposing))
Yang Xiangyu; Xiong Guifang; Yang Jie; Ma Xinyi; Qie Yuanzheng — International immunopharmacology 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, treatment-target

Vilazodone directly inhibits NLRP3 inflammasome assembly (NACHT domain) and reduces MSU-induced inflammation, offering a potential repurposed therapeutic candidate relevant to the GOLD (uric acid/MSU-NLRP3) and general NLRP3 hyperactivation streams in this interferon-mitochondrial syndrome.
DOI: 10.1016/j.intimp.2026.117279

Novel natural inhibitor Rubimaillin targets NLRP3 R167/Y381 to ameliorate inflammatory and neurodegenerative diseases. (from Ethnopharmacology/natural product drug discovery)
Xiao Jing; Lan Zhen; Zhang Ran; Zhang Jie; Hu Zuobin — Journal of ethnopharmacology 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, treatment-target

Identifies a natural NLRP3 inhibitor effective in gouty arthritis (MSU-induced, matching the GOLD pathway) and neurodegenerative models, offering a potential therapeutic candidate relevant to the NLRP3 hyperactivation axis in this syndrome.
DOI: 10.1016/j.jep.2026.122293

Lactate-Induced K370 Lactylation of STING Inhibits STING-TBK1 Signaling and Dampens Anti-Tumor Immunity. (from oncology/tumor immunometabolism)
Wu Yueyao; Wang Jingzhe; Chen Xu; Yang Yuntong; Wei Ping — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Reveals a novel post-translational (lactylation) regulatory checkpoint on STING-TBK1 signaling relevant to the BLUE loop's IFN-I output, though in an oncology/tumor immunity context rather than SAMHD1 interferonopathy.
DOI: 10.1002/advs.77209

Mechanistic machine learning for prediction of prime editing outcomes. (from computational genome editing / bioengineering)
Hsu Alvin; Chen Peter J; Li Angus H; Hemez Colin F; Gao Xin D — Nature biotechnology 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery

This paper presents a machine learning tool (OptiPrime) for optimizing prime editing efficiency, directly relevant to future gene correction strategies for missense mutations like SAMHD1 p.A565T, though it does not address SAMHD1 or the interferon-mitochondrial mechanism itself.
DOI: 10.1038/s41587-026-03261-7

Advances in paclitaxel-mediated remodeling of the gastric cancer immune microenvironment and sensitization to immune checkpoint inhibitors via cGAS-STING pathway activation triggered by mtDNA release: challenges and translational perspectives. (from Oncology (gastric cancer chemo-immunotherapy))
Wu Chu-Ying; Sun Zun-Long; Ye Kai — 2026
Score: 5/10 | Pathways: cGAS-STING, treatment-target, other

Describes mtDNA release activating cGAS-STING/type I interferon signaling, mechanistically overlapping with the BLUE loop, but in an oncology chemotherapy context unrelated to SAMHD1 or the family phenotype.
DOI: 10.1007/s11033-026-12570-8

Mitochondrial Dysfunction as a Driver of Meta-Inflammation in Aging: The Emerging Role of PDK4 in Bioenergetic Reprogramming and Inflammatory Amplification. (from metabolic/aging biology and endocrinology)
Chowdhury Md Riad; Jeong Gui-Hwa; Lee In-Kyu — 2026
Score: 5/10 | Pathways: NLRP3, cGAS-STING, NF-kB-IKK, mito-ROS-NF-kB, other

Reviews mitochondrial dysfunction driving NF-κB/NLRP3/cGAS-STING-mediated meta-inflammation via PDK4/pyruvate metabolism, an adjacent metabolic-inflammatory mechanism relevant to the family's mitochondrial-interferon axis but not SAMHD1-specific.
DOI: 10.3390/cells15151404

eVLP compound delivery breaks the prime editing efficiency ceiling. (from gene therapy/genome editing engineering)
Wang Margaret R; Sánchez-Rivera Francisco J — Cell genomics 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery

Describes an engineered virus-like particle (eVLP) repeated-dosing strategy (PRIME-VLP) that improves prime editing efficiency, relevant as a potential future delivery platform for correcting SAMHD1 point mutations but not disease-mechanism specific.
DOI: 10.1016/j.xgen.2026.101333

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata. (from Dermatology)
Mochón-Jiménez Carmen; Gay-Mimbrera Jesús; Dávila-Flores Viviana; He Helen; Zhou — Allergy 2026
Score: 4/10 | Pathways: JAK-STAT, treatment-target

Alopecia areata tape-strip transcriptomics highlights IFN/JAK-STAT and baricitinib response signatures, mechanistically adjacent to the interferonopathy axis but not connected to SAMHD1 or the family's core mitochondrial-inflammasome pathways.
DOI: 10.1111/all.70293

Ultra-sensitive profiling of CRISPR-Cas off-target effects with Tracking-seq2 (from genomics/bioinformatics methodology)
Tingting Cong; Runda Xu; Xuancheng Chen; Junsong Yuan; Zuomiao Lin — Nature Communications 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

This paper presents an off-target detection method for CRISPR editors relevant to future gene correction of SAMHD1 variants but has no direct disease mechanism or immune pathway content.
DOI: 10.1038/s41467-026-76778-9

Inflammatory kinase TBK1 suppresses homologous recombination DNA repair to sensitize tumors to chemotherapy. (from Oncology/DNA damage response)
Zhou Wei; Wang Xiangyu; Steigleder Susanne S; Xing Aowei; Yang Dan — Proceedings of the National Academy of Sciences of the United States of America 2026
Score: 4/10 | Pathways: NF-kB-IKK, other

TBK1 (IKKε/TBK1 axis) is a named kinase in the interferonopathy mechanism, but this paper focuses on its DNA-repair/chemotherapy role independent of cytokine or STING/IRF3 signaling, making it only tangentially relevant.
DOI: 10.1073/pnas.2533402123

Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts (from Neuromuscular genetics / gene therapy)
A. Siddika; F. Husseiny; J. Rousseau; J. Tremblay — International Journal of Molecular Sciences 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

Demonstrates a generalizable prime editing correction workflow for a pathogenic point mutation restoring protein expression, methodologically relevant to future SAMHD1 A565T correction but unrelated disease (DMD) and non-immune cell type.
DOI: 10.3390/ijms27156927

In Vivo Base Editing for Neonatal Inborn Errors of Metabolism: Clinical Progress, N-of-1 Therapy, and the Ethics of Bespoke Genetic Medicine. (from Neonatology/Genetic Medicine Ethics)
Li Oscar Mingtian; Li Yijiang; Li Summer Xia Tian — Cureus 2026
Score: 4/10 | Pathways: gene-therapy-delivery, prime-editing

This paper reviews in vivo base editing for neonatal metabolic disorders using LNP delivery, relevant as a generalizable precedent for correcting a heterozygous missense variant like SAMHD1 A565T but not targeting immune/myeloid cells or the interferon-mitochondrial mechanism directly.
DOI: 10.7759/cureus.114354

From mechanical adaptation to innate immune reprogramming in osteoarthritis: a load-immunity framework (from Orthopedics/Rheumatology (mechanobiology of joint disease))
Shiguo Zuo; Lijun He; Z. Hou; Quanliang Tian; Yilong Yang — Frontiers in Immunology 2026
Score: 4/10 | Pathways: cGAS-STING, NLRP3, other

This osteoarthritis review discusses cGAS-STING and NLRP3 signaling in mechanotransduction and mitochondrial danger signal propagation, mechanistically adjacent but not directly tied to SAMHD1 biology or the interferon-mitochondrial syndrome described.
DOI: 10.3389/fimmu.2026.1931112

Liver Organoids: From Disease Modelling to Regenerative Medicine. (from Hepatology/regenerative medicine)
Wang Tiepeng; Qu Xiaotian; Si Jinhong; Meng Junkang; Zhang Ting — Cell proliferation 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery

This is a general liver organoid review with only a passing mention of prime editing correction in patient-derived organoids and no SAMHD1, interferon, NLRP3, or mitochondrial dNTP pathway content relevant to the family phenotype.
DOI: 10.1111/cpr.70268

Hierarchical Core-Shell Nanoplatform with Sequential Mn<sup>2+</sup>/Co<sup>2+</sup> Release Enables Dual-Track STING Amplification and Radiosensitization for Potent Radio-Metalloimmunotherapy. (from Oncology/nanomedicine radiotherapy)
Luo Baiyi; Xiang Qingming; Xie Yingling; Wang Shuo; Xu Yu — 2026
Score: 3/10 | Pathways: cGAS-STING

Paper uses cGAS-STING pathway activation as a cancer nanomedicine strategy via metal ion delivery, unrelated to SAMHD1 mechanism or mitochondrial dNTP dysregulation despite shared pathway terminology.
DOI: 10.1016/j.actbio.2026.08.012

Estrogen Withdrawal-Induced Cognitive Impairment in Menopausal Women: Mechanisms and Prospects for Integrated Interventions. (from Neurology/Endocrinology)
Qiu Tiantian; Zhang Junying; Zhao Jiayou — International journal of molecular sciences 2026
Score: 3/10 | Pathways: NLRP3, mito-ROS-NF-kB

Discusses NLRP3 inflammasome and mitochondrial dysfunction in menopausal cognitive decline, sharing mechanistic overlap with the interferon-mitochondrial syndrome but unrelated to SAMHD1 or its specific pathways.
DOI: 10.3390/ijms27157003

The APC/C subunit APC7 exerts antiviral effects by targeting the adaptor protein MAVS (from Virology/cell biology (RIG-I-MAVS antiviral signaling))
Rui Su; Aiping Sun; Yifan Niu; Tiesuo Zhao; Hui Wang — Frontiers in Immunology 2026
Score: 3/10 | Pathways: other

This paper concerns RIG-I/MAVS antiviral signaling and IFN-I induction via a distinct APC7-MAVS ubiquitination mechanism, not overlapping with SAMHD1/cGAS-STING/NLRP3/NF-kB pathways central to the disease profile.
DOI: 10.3389/fimmu.2026.1912055

Extracellular vesicle-mediated immune crosstalk in rheumatoid arthritis synovium: mechanistic insights and translational challenges (from Rheumatology)
Feng Luo; Xuemei Yuan; Heng Zhou; Qiuyi Wang; Changming Chen — Frontiers in Immunology 2026
Score: 3/10 | Pathways: cGAS-STING, JAK-STAT, NF-kB-IKK, clinical-phenotype

This RA-focused review touches on cGAS-STING, NF-κB, and JAK-STAT signaling and mentions RA (a tracked family phenotype), but it centers on extracellular vesicle biology in synovium without any connection to SAMHD1, dNTP metabolism, or the core mitochondrial-interferon mechanism.
DOI: 10.3389/fimmu.2026.1891984

Targeting the hallmarks of ageing: Pharmacological challenges and breakthroughs in CRISPR delivery systems and future prospects. (from Gerontology/pharmacology (CRISPR delivery technology))
Rathore Sakshi; Gupta Akash; Shah Kamal; Chauhan Nagendra Singh; Gupta Sanjay Ku — Ageing research reviews 2026
Score: 3/10 | Pathways: gene-therapy-delivery, prime-editing

General CRISPR delivery/ageing review with only generic mention of prime/base editing and mitochondrial dysfunction, lacking any SAMHD1, immune, or myeloid-specific delivery focus relevant to this disease.
DOI: 10.1016/j.arr.2026.103301

Expanding the clinical spectrum of DNASE1L3-associated monogenic lupus: A case series of 4 syrian pediatric cases. (from Pediatric Rheumatology/Nephrology)
Kousa Alyamama; Alhamwi Ahmad; Alsayed Mohammad Khaled; Jabaly Sara; Khalil Bash — Medicine 2026
Score: 3/10 | Pathways: AGS-spectrum, clinical-phenotype, treatment-target

DNASE1L3 monogenic lupus is a distinct autosomal-recessive nucleic acid clearance disorder in the broader interferonopathy/autoimmune spectrum, but does not involve SAMHD1, dNTPase, cGAS-STING, or the mitochondrial-NLRP3 axis central to this profile, though baricitinib use is a tangential JAK-inhibitor overlap.
DOI: 10.1097/MD.0000000000050283


Pathway Coverage This Week

  • cGAS-STING: 13 papers
  • treatment-target: 13 papers
  • NLRP3: 7 papers
  • prime-editing: 7 papers
  • gene-therapy-delivery: 7 papers
  • NF-kB-IKK: 6 papers
  • other: 6 papers
  • mito-ROS-NF-kB: 4 papers
  • clinical-phenotype: 4 papers
  • POLG-mtDNA: 2 papers
  • urate-NLRP3: 2 papers
  • JAK-STAT: 2 papers
  • VDAC1: 1 papers
  • mito-dNTP-transport: 1 papers
  • ISG15-mitophagy: 1 papers
  • AGS-spectrum: 1 papers

SAMHD1 Research Digest — 2026-08-09

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 21 papers evaluated | 2 high-relevance (≥7) | 9 medium (5–6) | 10 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Senkyunolide I Inhibits mtDNA-cGAS-STING Signaling in Macrophages via Targeting VDAC1 Oligomerization to Attenuate Ulcerative Colitis. (from Gastroenterology (ulcerative colitis/IBD))
Ye Zhiming; Huang Yihang; Han Bohao; Zhang Lei; Yu Can — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 8/10 | Pathways: cGAS-STING, VDAC1, NLRP3, treatment-target

Directly demonstrates VDAC1 oligomerization-mediated mtDNA release driving cGAS-STING-NLRP3 activation in macrophages, mechanistically identical to the BLUE loop, with a novel small-molecule inhibitor (SEI) analogous to VBIT-4 as a therapeutic strategy.
DOI: 10.1002/advs.77045

Yiqi Huoxue Jiedu formula protects against sepsis-associated lung injury by modulating macrophage mitophagy and mtDNA-STING signaling. (from Traditional Chinese Medicine / critical care sepsis pulmonology)
Ma Shuqi; Pan Qiusha; Lin Jingnan; Zeng Ruifeng; Xi Xiaotu — Chinese medicine 2026
Score: 7/10 | Pathways: cGAS-STING, VDAC1, treatment-target, mito-ROS-NF-kB

Demonstrates a PINK1/Parkin mitophagy–mtDNA leakage–cGAS-STING-TBK1-IRF3-IFN-I axis in macrophages, directly paralleling the BLUE/RED loops and mitophagy blockade mechanisms central to the SAMHD1 syndrome model, with a botanical treatment implication for mitophagy restoration.
DOI: 10.1186/s13020-026-01475-0

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

The dual role of the cGAS-STING signaling pathway in kidney diseases: from acute injury to chronic fibrosis – molecular mechanisms and precision therapeutic strategies (from Nephrology)
Guangdong Qi; Fei Xue; Hualin Sun; Xinlei Yao; Qingyuan Liu — Frontiers in Pharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, NF-kB-IKK

Reviews cGAS-STING mechanisms (mtDNA leakage, TBK1-IRF3/NF-κB, PERK-eIF2α) and inhibitor strategies (H-151, RU.521) directly relevant to the BLUE loop's core signaling axis, though applied to renal rather than SAMHD1-driven disease.
DOI: 10.3389/fphar.2026.1882994

Maternal hyperglycemia-induced O-GlcNAcylation of CaMKIIδ promotes mtDNA release and cardiac remodeling in offspring. (from Cardiology/Obstetrics (maternal-fetal medicine and pediatric cardiology))
Xiao Zemeng; Gao Ling; Wang Yuehong; Yang Chunli; Qian Yuxuan — 2026
Score: 6/10 | Pathways: cGAS-STING, pregnancy-fetal, NF-kB-IKK, clinical-phenotype

This paper demonstrates a mtDNA-release → cGAS-STING → inflammation axis in cardiac tissue analogous to the BLUE loop mechanism in the SAMHD1 profile, with pregnancy/fetal programming relevance to the family's obstetric phenotype tracking.
DOI: 10.1038/s41467-026-75630-4

Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome (from Clinical immunology/rare monogenic autoinflammatory disease)
Sara G. Hamad; Melanie Makhlouf; N. Agrebi; A. Kaddourah; M. Abu-Hasan — Journal of Clinical Immunology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, IRF7-metabolic, AGS-spectrum, clinical-phenotype, treatment-target

ZNFX1 deficiency is a related type I interferonopathy involving MAVS/ISG dysregulation with NF-kB/NLRP3-adjacent inflammatory cytokine (TNF, IL-1beta) crosstalk and macrophage activation syndrome, offering mechanistic and clinical analogy to the SAMHD1 interferon-mitochondrial syndrome despite a distinct causal gene.
DOI: 10.1007/s10875-026-02056-4

Hyper-aging in systemic sclerosis: linking genome instability, mitochondrial dysfunction, and inflammaging to fibrosis. (from Rheumatology (systemic sclerosis/aging biology))
Mohammad Waseem; Azait Imtiaz; Amit Datta; Rafael Contreras-Galindo — Current opinion in rheumatology 2026
Score: 6/10 | Pathways: cGAS-STING, POLG-mtDNA, treatment-target, clinical-phenotype

Describes cytosolic DNA (nuclear/mitochondrial)-driven cGAS-STING/type I IFN activation, mitochondrial dysfunction, and genome instability driving fibrosis in systemic sclerosis, mechanistically paralleling the BLUE/RED interferonopathy streams and suggesting rheumatologic phenotype overlap relevant to the family's autoimmune/mitochondrial spectrum.
DOI: 10.1097/BOR.0000000000001181

AI Designed Conformation Locking Peptides Target STING to Restore Diabetic Wound Healing. (from dermatology/wound healing and biomaterials engineering)
Li Xinyu; Fu Haojie; Wang Zhe; Chen Xuanzhou; Zhang Ruhong — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

This paper targets the STING-TBK1-IRF3 axis directly implicated in the disease's BLUE loop, offering a novel therapeutic conformation-locking peptide strategy relevant to interferonopathy suppression, though applied to diabetic wound healing rather than SAMHD1-related pathology.
DOI: 10.1002/advs.76849

DNA Sensing Pathways in Innate Immunity: Implications for Alzheimer’s Disease Progression and Therapy (from neurology/neurodegeneration)
Chenmo Shi; Ye Liu; Yanli Zhu — Molecular Neurobiology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, treatment-target

Reviews cGAS-STING/AIM2/TLR9 DNA-sensing driving IFN-I and inflammasome-mediated neuroinflammation, directly relevant to the interferon-mitochondrial mechanism though applied to Alzheimer's rather than SAMHD1 disease, offering a neurology/neuroinflammation bridge to the family's neurologic phenotypes.
DOI: 10.1007/s12035-026-06081-7

The consequences of mitochondrial dysfunction and upregulated glycolysis on innate and adaptive immune responses (from Metabolic immunology / cancer immunometabolism)
Fabrizio Marcucci; Cristiano Rumio — Cell Signaling, Inflammation & Disease 2026
Score: 6/10 | Pathways: NLRP3, mito-ROS-NF-kB, POLG-mtDNA, other

Reviews oxidized mtDNA/ROS-driven innate immune activation and glycolytic immunomodulation converging on mitochondrial dysfunction, mechanistically adjacent to the NLRP3/mito-ROS-NF-kB streams in the SAMHD1 model but without cGAS-STING/NLRP3-specific inflammasome or SAMHD1 data.
DOI: 10.1186/s44505-026-00005-x

Impaired NADH-linked mitochondrial respiration disrupts ventral midbrain neuronal programs in POLG disease. (from Neurology/mitochondrial disease (stem cell organoid modeling))
Chen Anbin; Yangzom Tsering; Sullivan Gareth John; Liang Kristina Xiao — Journal of translational medicine 2026
Score: 6/10 | Pathways: POLG-mtDNA, treatment-target

This paper studies POLG mutations causing mitochondrial DNA instability and impaired oxidative phosphorylation in dopaminergic neurons, directly relevant to the PURPLE stream's POLG stalling mechanism even though it lacks any immune/inflammasome readout.
DOI: 10.1186/s12967-026-08706-w

Early versus late JAK-STAT-IFN signaling distinguishes no rejection from subclinical to clinical TCMR after liver transplantation. (from Transplant hepatology/immunology)
Macedo Camila; Hadjiyannis Yannis; Tran Lillian M; Elinoff Beth D; Abukhiran Ibr — Science translational medicine 2026
Score: 5/10 | Pathways: JAK-STAT, treatment-target

Demonstrates biphasic JAK-STAT/interferon-stimulated gene signaling driving T cell-mediated rejection and validates ruxolitinib (a JAK inhibitor relevant to the disease's IFN-I axis) as a therapeutic strategy, though not SAMHD1-specific.
DOI: 10.1126/scitranslmed.aec4107

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

SAMHD1 enhances HIV-1-induced glycolysis in monocytic cells through hexokinase 2 upregulation (from Virology/HIV metabolism)
Yang Hua; Cheung Pak-Hin Hinson; Wu Li — 2026
Score: 4/10 | Pathways: dNTPase, mito-ROS-NF-kB, other

This paper explores a novel SAMHD1 function in HIV-1-induced glycolysis and mitochondrial ROS in monocytic cells, which is tangential to the interferon-mitochondrial-NLRP3 axis central to the A565T phenotype but still reinforces SAMHD1's broader mitochondrial regulatory role.
DOI: 10.64898/2026.08.03.742570

Precision correction of the GJB2 c.235delC mutation by prime editing in vitro. (from Otology/audiology gene therapy)
Jin Jiang; Lv Xiujuan; Li Yangyang; Xu Yaoyao; Chen Lei — Gene therapy 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

This paper demonstrates a generalizable prime editing/dual-AAV correction toolkit for a monogenic point mutation, methodologically relevant to future SAMHD1 missense correction but unrelated to GJB2's disease mechanism or the interferon-mitochondrial pathways.
DOI: 10.1038/s41434-026-00638-w

AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy (from Pharmaceutics/Drug Delivery Engineering)
Bowen Li — Cell and Gene Therapy Insights 2026
Score: 4/10 | Pathways: gene-therapy-delivery

Discusses general AI-guided LNP design for non-viral gene therapy delivery, relevant as a future therapeutic platform but not specific to SAMHD1, myeloid/immune tissue targeting, or interferon-mitochondrial mechanisms.
DOI: 10.18609/cgti.2026.082

Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells. (from Cell and gene therapy manufacturing / oncology immunotherapy)
Ferrara Francesca; Wielgosz Matthew M; Park Jeoungeun J; Bauler Matthew; Wincek * — Molecular therapy. Advances 2026
Score:
4/10* | Pathways: gene-therapy-delivery

This paper describes VLP/lentiviral delivery of Cas9 RNPs for CAR T cell manufacturing, relevant as a general gene-editing delivery platform but not tied to SAMHD1 correction, myeloid tropism, or precision missense correction like prime editing.
DOI: 10.1016/j.omta.2026.201809

Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts (from Muscular dystrophy/gene therapy)
A. Siddika; F. Husseiny; J. Rousseau; J. Tremblay — International Journal of Molecular Sciences 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery

This paper demonstrates a prime editing correction platform in muscle cells for DMD, technically relevant to gene correction methodology but not targeting immune/myeloid cells or the SAMHD1 pathway.
DOI: 10.3390/ijms27156927

Mitochondrial transfer in the tumor microenvironment: mechanisms, immunometabolic consequences, and therapeutic implications. (from Oncology/tumor immunology)
Feng Sijia; Hu Yanan; Li Shuqing; Chang Yuqiao; Li Zhenwei — Critical reviews in oncology/hematology 2026
Score: 3/10 | Pathways: cGAS-STING, NLRP3, other

Discusses mtDNA-driven cGAS-STING/NLRP3/TLR9 signaling and mitochondrial transfer in tumor immunometabolism, tangentially touching core pathways but in an oncology tumor-microenvironment context unrelated to SAMHD1 mechanism.
DOI: 10.1016/j.critrevonc.2026.105530

Signaling pathways and ion channels in osteoarthritis: a review of recent advances (from Orthopedics/Rheumatology (osteoarthritis))
Xi Liu; Niqing Xiao; Qiumei He; Kuanmeng Chi; Hongting Lu — Frontiers in Immunology 2026
Score: 3/10 | Pathways: NLRP3, cGAS-STING, NF-kB-IKK

This paper covers NF-κB, cGAS-STING, and NLRP3 signaling but in the context of osteoarthritis mechanobiology, with no connection to SAMHD1, interferonopathy, or the family phenotype spectrum.
DOI: 10.3389/fimmu.2026.1823905

Shi Pi Shu Gan Formula Prevents and Treats Sequelae of Pelvic Inflammatory Disease by Regulating PKA-CREB-Yap1 Signaling through the mtDNA/cGAS/STING Network. (from Traditional Chinese Medicine / Gynecology)
Mi Yuyang; He Haiqing; Huang Yefang; Huang Li; Li Maoya — 2026
Score: 3/10 | Pathways: cGAS-STING

Demonstrates mtDNA-cGAS-STING pathway activation and mitophagy regulation in a rat model of pelvic inflammatory disease using a TCM herbal formula, sharing core mechanistic pathway but unrelated to SAMHD1 or the family phenotype spectrum.
DOI: 10.2174/0118715303458984260714211650

Respiratory syncytial virus inhibits type I interferon signaling to maintain HLA-DM expression in CD1c+ dendritic cells. (from Virology/Dendritic cell immunology)
Ong Weiyee; Hopkins Richard Anthony; Yang Enjun; Novita; Talib Najwa — iScience 2026
Score: 3/10 | Pathways: JAK-STAT, other

This paper concerns TBK1-dependent Type I IFN signaling regulating HLA-DM/antigen presentation in RSV-infected dendritic cells, touching on IFN-I pathway machinery but not on SAMHD1, mitochondrial dysfunction, or inflammasome mechanisms central to the disease profile.
DOI: 10.1016/j.isci.2026.116736

Comparative Analysis of LPS/IFN-γ and LPS/ATP-Induced Inflammatory Models in BV2 Microglia. (from Neuroinflammation/microglial pharmacology)
Zhang Xinfeng; Lian Zhuo; Lei Sijie; Yi Tanhui; Zhao Shuyin — Neurochemical research 2026
Score: 3/10 | Pathways: NLRP3

This paper compares in vitro microglial inflammation models using NLRP3/IL-1beta and NO/TNF-alpha readouts but does not involve SAMHD1, cGAS-STING, mitochondrial dNTP transport, or any disease-specific mechanism relevant to the profile.
DOI: 10.1007/s11064-026-04853-0


Pathway Coverage This Week

  • cGAS-STING: 11 papers
  • treatment-target: 9 papers
  • NLRP3: 7 papers
  • other: 4 papers
  • gene-therapy-delivery: 4 papers
  • mito-ROS-NF-kB: 3 papers
  • NF-kB-IKK: 3 papers
  • clinical-phenotype: 3 papers
  • POLG-mtDNA: 3 papers
  • VDAC1: 2 papers
  • JAK-STAT: 2 papers
  • prime-editing: 2 papers
  • pregnancy-fetal: 1 papers
  • IRF7-metabolic: 1 papers
  • AGS-spectrum: 1 papers
  • dNTPase: 1 papers

SAMHD1 Research Digest — 2026-08-05

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 9 papers evaluated | 3 high-relevance (≥7) | 3 medium (5–6) | 3 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Circadian rhythm disruption induces cardiac hypertrophy via promoting the mtDNA release-activated cGAS-STING pathway. (from Cardiology)
Ouyang Zizhang; Luo Runqi; Li Jingxuan; Huang Qiuyan; Chen Ziying — 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, clinical-phenotype

Demonstrates mtDNA release-driven cGAS-STING activation causing cardiac hypertrophy, directly relevant to Loop A mechanism and the family's cardiac/mitochondrial-interferonopathy phenotype spectrum.
DOI: 10.1016/j.bcp.2026.118309

ATP6AP2 ameliorates inflammation and pyroptosis in heart failure by promoting lysosome-dependent STING degradation. (from Cardiology)
Zhao Xuan; Zhang Hui; Ding Xinyue; Wu Huimin; Li Min — Apoptosis : an international journal on programmed cell death 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, NLRP3, mTOR-lysosomal

Demonstrates lysosome-mediated STING degradation regulating STING-TBK1-IRF3 signaling and downstream pyroptosis/inflammation in a cardiac model, directly relevant to the BLUE loop's cGAS-STING axis and cardiac interferonopathy phenotype relevant to family cardiology risk.
DOI: 10.1007/s10495-026-02415-x

JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients. (from Pediatric rheumatology/autoinflammatory disease)
Vahabi Seyed Mohammad; Pourgholi Elnaz; Leblebici Can Berk; Crisler William J; H — European journal of pediatrics 2026
Score: 7/10 | Pathways: JAK-STAT, AGS-spectrum, treatment-target

CANDLE is a proteasome-associated type I interferonopathy successfully treated with JAK inhibitors (baricitinib/tofacitinib), directly supporting the JAK-STAT axis and JAK-inhibitor therapeutic strategy relevant to SAMHD1-driven interferonopathy.
DOI: 10.1007/s00431-026-07293-8

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling (from Oncology/hematology)
Huan Chen; N. An; Linlin Yang; Jin Lou; Yuming Pan — Extracellular Vesicles and Circulating Nucleic Acids 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, gene-therapy-delivery

Demonstrates mtDNA leakage-driven cGAS-STING-IFN-I activation via a TFAM-mitochondrial genome instability axis analogous to the BLUE pathway, plus EV-siRNA delivery relevant to future targeted therapeutics, though in an oncology (AML) rather than SAMHD1 context.
DOI: 10.20517/evcna.2026.36

Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF-κB and NLRP3 Signaling Pathways. (from Nephrology/Cardiology pharmacology (natural compound therapeutics for hyperuricemia-induced organ damage))
Li Yongmei; Xu Yuexin; Ye Wenjie; Yu Zeqi; Wu Zhenkun — Journal of biochemical and molecular toxicology 2026
Score: 6/10 | Pathways: urate-NLRP3, NF-kB-NLRP3-priming, NLRP3, treatment-target

This paper demonstrates that uric acid drives NF-κB/NLRP3 inflammasome activation causing renal and cardiac injury, directly modeling the GOLD pathway (dGTP→purine catabolism→uric acid→NLRP3) and NF-κB-NLRP3 priming crosstalk relevant to SAMHD1-driven interferonopathy, though it lacks any SAMHD1 or interferon-specific mechanism.
DOI: 10.1002/jbt.71058

Advancements in Diagnosis and Care for Immune Dysregulation and Inborn Errors of Immunity in Pediatric Rheumatology - Our 50-year Journey. (from Pediatric rheumatology)
M. Day-Lewis; Jennifer L Cheng; Edward M. Behrens; Melissa M Hazen; E. Janssen — Arthritis care & research 2026
Score: 5/10 | Pathways: cGAS-STING, NLRP3, JAK-STAT, AGS-spectrum, treatment-target, clinical-phenotype

General review of pediatric rheumatology's role in interferonopathies and inflammasome-driven disease provides relevant clinical/therapeutic framing (JAK inhibitors, IL-1/IL-18 targeting) but lacks specific SAMHD1 or mechanistic pathway data.
DOI: 10.1002/acr.80127

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

IFI16/204 Promotes Dendritic Cell Activation and Anti-Hepatocellular Carcinoma Efficacy via the STING-TBK1-IRF3 Signalling Pathway. (from Oncology/Hepatology (tumor immunology))
Zhang Long; He Wenjing; Zhang Hanyuan; Zhang Xuzhi; Wang Hanyu — Immunology 2026
Score: 4/10 | Pathways: cGAS-STING, other

This paper demonstrates STING-TBK1-IRF3 signaling driving IFN-I-related dendritic cell activation, a downstream node in the BLUE pathway, but is focused on anti-tumor immunity in HCC rather than SAMHD1 biology, mitochondrial dysfunction, or the interferonopathy syndrome described.
DOI: 10.1111/imm.70152

Imaging Findings of Pediatric Rheumatic Disorders: JIA in the PRINTO Era and Autoimmune Interferonopathies. (from Pediatric radiology/rheumatology)
Y. Tsujioka; Yoshitake Yamada; Gen Nishimura; Tatsuo Kono; Masahiro Jinzaki — Pediatrics international : official journal of the Japan Pediatric Society 2026
Score: 3/10 | Pathways: JAK-STAT, AGS-spectrum, clinical-phenotype

This is a general pediatric rheumatology imaging review that mentions interferonopathies as a conceptual framework but provides no mechanistic or SAMHD1-specific data relevant to the disease profile.
DOI: 10.1111/ped.70487

CRISPR-Based Genome Editing in Contemporary Clinical Medicine: Therapeutic Translation, Global Challenges and the Future of Precision Medicine (from genomic medicine/regulatory policy)
Gabriel Alejandro Ortega Moreno; Gerardo Amaya Villagran; Andrés Mauricio Umaña * — International Science Journal 2026
Score:
3/10* | Pathways: gene-therapy-delivery, prime-editing

General CRISPR clinical translation review with no mention of SAMHD1 or related interferon/mitochondrial pathways, only tangentially relevant as background on gene editing platforms that could theoretically correct SAMHD1 variants.
DOI: 10.64784/277


Pathway Coverage This Week

  • treatment-target: 6 papers
  • cGAS-STING: 5 papers
  • clinical-phenotype: 3 papers
  • NLRP3: 3 papers
  • JAK-STAT: 3 papers
  • AGS-spectrum: 3 papers
  • gene-therapy-delivery: 2 papers
  • mTOR-lysosomal: 1 papers
  • urate-NLRP3: 1 papers
  • NF-kB-NLRP3-priming: 1 papers
  • other: 1 papers
  • prime-editing: 1 papers

SAMHD1 Research Digest — 2026-08-02

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 24 papers evaluated | 2 high-relevance (≥7) | 13 medium (5–6) | 9 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Mitochondrial DNA oxidation propagates autoimmunity by enabling plasmacytoid dendritic cells to induce TFH differentiation 2253320 (from Rheumatology/Autoimmunity)
Hongxu Xian; Michael Karin — The Journal of Immunology 2026
Score: 8/10 | Pathways: NLRP3, cGAS-STING, IRF7-metabolic, POLG-mtDNA, NF-kB-NLRP3-priming, clinical-phenotype

Demonstrates that oxidized mtDNA released via NLRP3/caspase-1/gasdermin-D drives pDC-mediated IL-1β and IFN-α signaling to promote TFH differentiation and autoantibody-driven autoimmunity, directly reinforcing the ox-mtDNA-NLRP3-IFN convergence central to the SAMHD1 A565T mechanism and its autoimmune/rheumatologic phenotype spectrum.
DOI: 10.1093/jimmun/vkag141.168

Pannexin1 promotes cellular senescence by triggering mtDNA release to activate the cGAS-STING pathway. (from Nephrology (acute kidney injury/chronic kidney disease and cellular senescence))
Li Jiaqi; Zhao Xin; Shen Yanting; Huang Liuwei; Guo Jie — 2026
Score: 7/10 | Pathways: cGAS-STING, NF-kB-IKK, VDAC1, treatment-target

This paper demonstrates mtDNA release via mPTP/BAX activating cGAS-STING to drive NF-κB-mediated SASP and IRF3 interferon output, directly paralleling the BLUE/Loop A mechanism (mtDNA escape → cGAS → STING → IFN-I plus NF-κB crosstalk) central to the SAMHD1 interferon-mitochondrial syndrome, though in a renal senescence rather than SAMHD1 context.
DOI: 10.1016/j.bbadis.2026.168388

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Diazonium-Enabled Post-Synthetic Construction of Enantiomeric Single-Atom Nanoagents Used for Alzheimer's Disease Treatment. (from Neurology/Nanomedicine)
Ya Junlin; Liu Mengmeng; Ji Yanjun; Tong Zhibo; Luo Bin — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Demonstrates mtDNA leakage-driven cGAS-STING activation in neuroinflammation and a nanoagent therapeutic strategy directly targeting this core pathway, relevant to the interferon-mitochondrial mechanism though not SAMHD1-specific.
DOI: 10.1002/smll.74610

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets. (from Cardiology)
Rong Jiaxiang; Wang Zhen; Lin Xiaoxiao; Lei Ziwen; Huang Qianqian — 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, NF-kB-IKK, mito-ROS-NF-kB, treatment-target, clinical-phenotype

This review synthesizes cGAS-STING, NLRP3, and mitochondrial DAMP-driven inflammatory circuits in cardiovascular disease that mechanistically overlap with the SAMHD1-driven interferon-mitochondrial pathways implicated in the family's cardiac and metabolic phenotypes, though it does not address SAMHD1 directly.
DOI: 10.1002/mco2.70878

Mito-TEMPO attenuates LPS-induced acute lung injury accompanied by ferroptosis suppression and reduced HSP90-STING association. (from Pulmonology/critical care)
Yao Yun; Guo Wei; Tian Yujia; Zeng Lisheng; Xia Xin — International immunopharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, mito-ROS-NF-kB, treatment-target

Demonstrates mitochondrial ROS scavenging (Mito-TEMPO) disrupting STING signaling (via HSP90-STING/TBK1-IRF3) and downstream ferroptosis in acute lung injury, directly paralleling the BLUE pathway's cGAS-STING-IFN axis and mito-ROS/NF-kB crosstalk relevant to interferonopathy-driven mitochondrial damage.
DOI: 10.1016/j.intimp.2026.117210

Modulation of Toll-like receptor driven monocyte activation by JAK-STAT inhibitors in people with HIV. (from Infectious disease/HIV immunology)
Camard Marion; Plaçais Léo; Bitu Marie; Mouanga Christelliah; Bourdic Katia — AIDS (London, England) 2026
Score: 6/10 | Pathways: JAK-STAT, treatment-target, clinical-phenotype

Demonstrates JAK-STAT inhibitors (baricitinib, a drug listed as therapeutically relevant) suppressing TLR-driven IFN-I monocyte activation, directly supporting the RED pathway/IFN-JAK-STAT axis therapeutic rationale relevant to SAMHD1 interferonopathy management.
DOI: 10.1097/QAD.0000000000004530

The Autophagy-Inflammasome Axis as a Molecular Switch: From Persistent Inflammation to Vascular Remodeling in IVIG-Resistant Kawasaki Disease. (from Pediatric rheumatology/cardiology (Kawasaki disease vasculitis))
Zhang Rong; Zhang Jiaqi; Yang Yanzhi; Wang Ya; Cao Haijun — 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, treatment-target, clinical-phenotype

Discusses mitophagy dysfunction driving cGAS-STING/NLRP3 inflammasome activation and IL-1β signaling in a pediatric vasculitis, mechanistically parallel to the SAMHD1 interferon-mitochondrial-inflammasome axis but in a distinct clinical context.
DOI: 10.3390/ijms27146405

Rocket-Inspired Sequentially Targeted Nanotherapeutics for Mitochondrial Regulation and Inflammatory Reprogramming in Ischemic Stroke. (from neurology/nanomedicine)
Bai He; Yong Zihao; Li Yang; Chen Qingmin; Liu Yong — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, other

Demonstrates a Drp1/mtDNA/cGAS-STING axis driving neuroinflammation with a mitochondrial-targeted nanotherapeutic, mechanistically adjacent (mtDNA release/cGAS-STING) though not SAMHD1-specific and in a different disease context (stroke).
DOI: 10.1002/advs.76859

Research Progress on Regulating Neuroinflammation After Spinal Cord Injury by Targeting the cGAS-STING Pathway. (from Neurosurgery/Spinal cord injury)
Xu Nanjian; Ma Weihu; Dong Weixin; Yu Liang — Neuromolecular medicine 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, treatment-target

Reviews cGAS-STING/mtDNA-driven NLRP3 activation and pyroptosis in neuroinflammation, mechanistically overlapping with Loop A/B and NLRP3 priming/activation core to the SAMHD1 syndrome, though in a spinal cord injury context rather than SAMHD1 disease.
DOI: 10.1007/s12017-026-08938-5

Köhlmeier-Degos disease is an interferonopathy characterized by type I and II interferon-driven inflammatory vasculopathy. (from Dermatology/Vasculopathy (rare disease immunology))
Cudrici Cornelia D; Goel Shubham; Sakamoto Keiko; Jin Seon-Pil; Sekiguchi Akiko — Cell reports. Medicine 2026
Score: 6/10 | Pathways: JAK-STAT, AGS-spectrum, treatment-target, clinical-phenotype

This paper demonstrates a type I/II interferonopathy vasculopathy responsive to JAK inhibition (ruxolitinib), directly paralleling the IFN-I-driven mechanism and JAK inhibitor therapeutic strategy relevant to SAMHD1-mediated interferonopathy, though it does not involve SAMHD1 or mitochondrial dNTP pathways.
DOI: 10.1016/j.xcrm.2026.102947

Exercise alleviates neuroinflammation and cognitive decline in aged mice via hepatic FGF21-driven microglial mitophagy. (from Neurology/Exercise Physiology)
Li Pengda; Wu Tao; Chen Mengjie; Wang Nan; Jia Xiaopeng — 2026
Score: 6/10 | Pathways: cGAS-STING, mTOR-lysosomal, treatment-target

The paper demonstrates cytosolic mtDNA accumulation driving cGAS-STING neuroinflammation and its reversal via AMPK-TFEB-mediated mitophagy, directly paralleling the BLUE loop and mitophagy-block mechanisms central to the SAMHD1 syndrome, though in an aging/exercise context rather than SAMHD1-specific.
DOI: 10.1016/j.bbi.2026.106935

Phase-dependent dynamics of circulating cell-free mitochondrial DNA reflect distinct immunometabolic states (from Infectious disease/tropical medicine (tuberculosis) and pediatric cardiac surgery)
Karen Alessandra Rodrigues; Emilly Henrique dos Santos; Gabriel Acca Barreira; M — Revista do Instituto de Medicina Tropical de São Paulo 2026
Score: 6/10 | Pathways: VDAC1, NLRP3, POLG-mtDNA, clinical-phenotype

Circulating cell-free mtDNA as a DAMP linking mitochondrial damage to innate immune activation is directly relevant to the BLUE/PURPLE loop mechanisms (VDAC1-mediated mtDNA release, NLRP3 activation) even though SAMHD1 is not studied.
DOI: 10.1590/S1678-9946202668048

Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model. (from Cardiology/metabolic physiology)
Mills Aimee R; de Souza Antonio; Pham Toan; Mugisho Odunayo O — Experimental physiology 2026
Score: 5/10 | Pathways: NLRP3, urate-NLRP3, treatment-target, other

Demonstrates a mitochondrial-derived peptide suppressing NLRP3 inflammasome activation (with uric acid correlation) in a diabetic cardiac model, relevant as an adjacent NLRP3/mitochondrial dysfunction mechanism and potential therapeutic strategy but not tied to SAMHD1/interferon pathways.
DOI: 10.1113/EP093714

Microglial immunometabolic reprogramming in Alzheimer's disease: From mitochondrial dysfunction and redox imbalance to NLRP3 inflammasome-driven neuroinflammation. (from Neurology/Alzheimer's disease neuroimmunology)
Li Siyu; Jin Juntao; Liu Yingying; Yuan Jing; Dong Yuhan — Journal of Alzheimer's disease : JAD 2026
Score: 5/10 | Pathways: NLRP3, mito-ROS-NF-kB, other

This review addresses mitochondrial dysfunction, oxidized mtDNA, and NLRP3 inflammasome activation in AD microglia, mechanistically overlapping with the PURPLE/GOLD/mito-ROS-NF-kB streams but in a neurodegenerative rather than SAMHD1-interferonopathy context.
DOI: 10.1177/13872877261469862

Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression. (from Hematology/gene therapy engineering)
Bandala-Sanchez Esther; Petley Emma V; Ramsay Kerry; Hilton Adrienne; White Chri — Blood 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery, treatment-target

Demonstrates multiplex prime editing to correct pathogenic immune-dysregulation variants and engineer drug-resistant T-cells, directly relevant as a translational platform for future correction of heterozygous missense mutations like SAMHD1 A565T in immune/myeloid cells, though not disease-specific.
DOI: 10.1182/blood.2026033156

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

FROM ONE-SIZE-FITS-ALL TO ON-DEMAND: PERSONALIZED CRISPR GENE EDITING FOR RARE GENETIC LIVER DISEASES. (from Hepatology/gene therapy)
Anh Tuan Quan — Clinics and research in hepatology and gastroenterology 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

This review covers CRISPR/base/prime editing and LNP delivery platforms for monogenic liver diseases, offering only general technological overlap with future SAMHD1 correction strategies but no direct SAMHD1, interferon, or mitochondrial pathway relevance.
DOI: 10.1016/j.clinre.2026.102892

CRISPR application in hematological disorders: from bench to bedside. (from Hematology/gene therapy)
Ladisa Francesco; Morelli Eugenio; Soncini Debora; Garibotto Matteo; Munshi Nikh — Blood advances 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

This is a general review of CRISPR/base/prime editing in hematologic diseases with no SAMHD1, interferon, or mitochondrial pathway content, only tangentially relevant as background on editing modalities that could theoretically correct a SAMHD1 missense variant in hematopoietic/myeloid cells.
DOI: 10.1182/bloodadvances.2025017417

Dual Roles of Free Fatty Acids in Gout Pathogenesis: Inflammatory Drivers and Metabolic Mediators. (from Rheumatology/metabolic lipidology)
Lin Na; Shao Chongyu — International journal of rheumatic diseases 2026
Score: 4/10 | Pathways: NLRP3, urate-NLRP3

Discusses FFA-driven NLRP3 activation and MSU crystal gout mechanisms which touch the GOLD pathway (uric acid-NLRP3 axis) but lacks any SAMHD1, interferon, or mitochondrial dNTP connection.
DOI: 10.1111/1756-185x.70799

Extracellular vesicle-mediated immune crosstalk in rheumatoid arthritis synovium: mechanistic insights and translational challenges (from Rheumatology/EV biology)
Feng Luo; Xuemei Yuan; Heng Zhou; Qiuyi Wang; Changming Chen — Frontiers in Immunology 2026
Score: 4/10 | Pathways: NF-kB-IKK, JAK-STAT, cGAS-STING, clinical-phenotype

This review discusses RA synovial EV-mediated NF-κB/JAK-STAT/cGAS-STING signaling, which touches on core interferonopathy pathways and matches the RA family phenotype, but has no direct SAMHD1, mitochondrial dNTP, or NLRP3 mechanistic link.
DOI: 10.3389/fimmu.2026.1891984

Rutin as a multi-target anti-inflammatory phytochemical in arthritic disorders: pharmacological mechanisms and therapeutic potential. (from Rheumatology/phytopharmacology)
Nazir Muhammad Muzammil; Ashraf Asma — Inflammopharmacology 2026
Score: 3/10 | Pathways: NLRP3, urate-NLRP3, NF-kB-IKK, JAK-STAT

This phytochemical review on rutin in arthritis touches tangentially on NLRP3, NF-κB, JAK-STAT, and urate pathways relevant to the GOLD stream and RA/gout family phenotypes, but has no connection to SAMHD1, interferon signaling, or mitochondrial mechanisms.
DOI: 10.1007/s10787-026-02351-x

Nanobody-STING Agonist Reprogram the Tumor Microenvironment and Improve Adoptive Cell Therapy for Solid Tumors 2309144 (from Oncology/immunotherapy)
Neil C. Chada; Alex Lee; H. Frank; Dawn K. Oh; Hannah Ki — The Journal of Immunology 2026
Score: 3/10 | Pathways: cGAS-STING, treatment-target

This paper uses a STING agonist to boost tumor immunity in oncology/immunotherapy context, tangential to the SAMHD1 disease's constitutive STING activation pathway but not addressing interferonopathy, SAMHD1, or mitochondrial dysfunction mechanisms.
DOI: 10.1093/jimmun/vkag141.1501

ESCAPE: assigning site-specific activity to covalent ligands in cells by prime editing (from chemical biology/cancer pharmacology)
Tse Jason; Brothers William; Hayward Rachel; Barbas Sabrina; Sheng Kai — preprint (preprint) 2026
Score: 3/10 | Pathways: prime-editing

This paper describes a general prime-editing-based functional genomics platform for covalent ligand characterization in cancer cell lines, unrelated to SAMHD1 biology, interferonopathy, or immune/myeloid gene correction strategies.
DOI: 10.64898/2026.07.28.741261

In vivo reconstruction of the cell lineage history of a developing mouse with DNA Typewriter, from zygote to late organogenesis (from Developmental biology/genomics)
Yu Qi; Kim Haedong; Seidel Sophie; Acosta-Clark James; Martin Beth — preprint (preprint) 2026
Score: 3/10 | Pathways: prime-editing

This paper demonstrates a prime editing-based lineage tracing technology in mouse embryos, which is only tangentially relevant as a general prime editing methodology advance rather than a myeloid/immune-targeted gene correction strategy applicable to SAMHD1 A565T.
DOI: 10.64898/2026.07.29.741625

Poly(I:C) and QS-21 combination suppresses breast tumor growth and metastasis by repolarizing tumor associated macrophages to anti-tumor macrophages. (from oncology/tumor immunology)
Zheng Haoxin; Jin Yanyan; Wang Zixuan; Yang Guang; Li Jianming — European journal of pharmacology 2026
Score: 3/10 | Pathways: JAK-STAT, cGAS-STING, treatment-target

This oncology-immunotherapy paper uses TBK1-IRF3/type I IFN and JAK-STAT signaling in macrophages, which overlaps mechanistically with the interferonopathy axis but is applied to TNBC immunotherapy rather than SAMHD1 biology.
DOI: 10.1016/j.ejphar.2026.179203


Pathway Coverage This Week

  • treatment-target: 14 papers
  • cGAS-STING: 12 papers
  • NLRP3: 9 papers
  • clinical-phenotype: 7 papers
  • JAK-STAT: 5 papers
  • prime-editing: 5 papers
  • NF-kB-IKK: 4 papers
  • mito-ROS-NF-kB: 3 papers
  • other: 3 papers
  • urate-NLRP3: 3 papers
  • gene-therapy-delivery: 3 papers
  • POLG-mtDNA: 2 papers
  • VDAC1: 2 papers
  • IRF7-metabolic: 1 papers
  • NF-kB-NLRP3-priming: 1 papers
  • AGS-spectrum: 1 papers
  • mTOR-lysosomal: 1 papers

SAMHD1 Research Digest — 2026-07-29

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 12 papers evaluated | 3 high-relevance (≥7) | 8 medium (5–6) | 1 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Mitophagy mitigates mitochondrial DNA-induced activation of cGAS-STING in autoimmune thyroiditis (from Endocrinology/Rheumatology—autoimmune thyroiditis model provides orthogonal evidence for cGAS-STING-driven tissue-specific autoimmunity that bridges to systemic interferonopathy phenotype in multi-system SAMHD1 families.)
Xiao-Chen Xie; Yang Guo; Ran Guo; Yong-Ze Li; Shan-Shan Wang — Nature Communications 2026
Score: 8/10 | Pathways: cGAS-STING, VDAC1, ISG15-mitophagy, POLG-mtDNA, mito-ROS-NF-kB, treatment-target, clinical-phenotype

Directly demonstrates mtDNA-cGAS-STING axis driving autoimmune disease via impaired mitophagy (PINK1/Parkin/TAX1BP1), mechanistically overlapping with the RED and BLUE loops in SAMHD1 A565T haploinsufficiency; identifies STING inhibition as therapeutic target applicable to convergent interferonopathy.
DOI: 10.1038/s41467-026-76047-9

NLRP3 Inhibitor KBD3536 Attenuates Acute Inflammation, Radiation-Induced Skin Injury, and Early Metabolic Dysfunction in Preclinical Models. (from Pharmacology/medicinal chemistry (NLRP3 inhibitor drug discovery and preclinical efficacy testing))
Qian Xinying; Ye Fei; Li Zhiyong; Chu Hongzhu; Xu Zeng — Pharmaceuticals (Basel, Switzerland) 2026
Score: 7/10 | Pathways: urate-NLRP3, NLRP3, NF-kB-IKK, treatment-target, clinical-phenotype

KBD3536 is a novel NLRP3 inhibitor with demonstrated efficacy in MSU-induced acute inflammation (gouty arthritis) and HFD-induced metabolic dysfunction—two pathologies directly implicated in the SAMHD1 A565T family phenotype (dGTP → purine catabolism → uric acid → MSU-NLRP3 axis; hepatic steatosis via IRF7-metabolic reprogramming); the paper provides preclinical validation of NLRP3 inhibition as a therapeutic strategy for this converged interferonopathy-metabolic syndrome.
DOI: 10.3390/ph19071083

CRISPR screening identifies GNPTAB as a noncanonical STING activator driving cellular senescence. (from Cell biology/gerontology—lysosomal biology and senescence mechanotransduction, not traditionally part of immunology or rheumatology training.)
Yin Jian; Gao Yizhou; Jing Yaobin; Jiang Xiaoyu; Wang Feibo — Protein & cell 2026
Score: 7/10 | Pathways: cGAS-STING, NF-kB-IKK, mTOR-lysosomal, treatment-target

GNPTAB-STING noncanonical activation via direct protein-protein interaction (E1119 interface) provides a novel upstream STING priming mechanism independent of canonical cGAS-mtDNA sensing; this represents an alternative route to STING/TBK1/NF-κB axis hyperactivation relevant to the BLUE and NF-κB crosstalk loops in A565T interferonopathy, with actionable therapeutic potential (STING-GNPTAB interface antagonism) for suppressing senescence-associated STING amplification.
DOI: 10.1093/procel/pwag049

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

DNAJB12/14 redox switching directs chaperone- and Bax/Bak-dependent ER protein reflux. (from Cell biology / ER stress and proteostasis; redox biochemistry)
Abu Madegam Laila; Gavriel Noa; Adebisi Raifu Tolulope; Igbaria Aeid — Redox biology 2026
Score: 6/10 | Pathways: BIK-cancer, mTOR-lysosomal, NF-kB-IKK, apoptosis-autophagy switch

BIK-mediated BAX/BAK recruitment to ER during severe ER stress mechanistically overlaps with the apoptosis-autophagy switch dysregulated in SAMHD1 haploinsufficiency, where ISGylation of BH3-only proteins and mitochondrial damage drive cell death; redox-sensitive DNAJB chaperone control of proteostasis and ER-to-cytosol signaling may modulate the severity of interferonopathy-driven ER stress in this family.
DOI: 10.1016/j.redox.2026.104324

Pectolinarigenin Attenuates LPS-Induced Lung Inflammation and Injury with Reduced HDAC3/NF-κB/NLRP3 Signaling. (from Pulmonology/immunotoxicology; plant natural products pharmacology)
Kim Danbee; Lee Dong-Keon; Park Jeong-Ran — Antioxidants (Basel, Switzerland) 2026
Score: 6/10 | Pathways: NLRP3, NF-kB-IKK, NF-kB-NLRP3-priming, treatment-target

Pectolinarigenin directly modulates the HDAC3/NF-κB/NLRP3 axis in LPS-induced inflammation, addressing two key steps in the proband's pathophysiology: NF-κB transcriptional priming of NLRP3 (Signal 1) and NLRP3 inflammasome activation (Signal 2); HDAC3 inhibition is a mechanistically novel approach to breaking the NF-κB–NLRP3 feed-forward loop and reducing mitochondrial ROS-driven inflammation, though the study uses acute LPS challenge rather than the chronic mitochondrial dNTP–oxMtDNA–NLRP3 circuit specific to SAMHD1 haploinsufficiency.
DOI: 10.3390/antiox15070898

Evolutionary history and recombination in the mitochondrial carrier SLC25 superfamily analyzed by similarities in the exon and transmembrane α‐helix sequences (from Evolutionary biology / structural proteomics)
Magnus Monné; D. V. Miniero; R. Calvello; A. Cianciulli; Luigi Palmieri — Protein Science : A Publication of the Protein Society 2026
Score: 6/10 | Pathways: mito-dNTP-transport, nucleotide-rewiring, other

This evolutionary/structural analysis of SLC25 superfamily (including PNC1/PNC2 nucleotide carriers) provides mechanistic foundation for understanding how substrate-specific subfamilies arose, directly relevant to the PNC1/2-mediated mitochondrial dNTP import bypass that drives NLRP3 hyperactivation in SAMHD1 haploinsufficiency; exon recombination patterns could illuminate functional specialization of dNTP transporters.
DOI: 10.1002/pro.70727

Synthetic Toll-Like Receptors for Control of Innate Immunity With Far-Red Light. (from Synthetic optogenetics/photobiology—a tool discipline offering potential mechanistic insight and future targeting strategy for the NF-κB and interferon regulatory axis but without direct mitochondrial, dNTPase, or disease-specific validation.)
Leopold Anna V; Verkhusha Vladislav V — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 6/10 | Pathways: NF-kB-IKK, IRF7-metabolic, treatment-target

Synthetic TLR optogenetics with MyD88→NF-κB/IRF3/IRF7 axis reprogramming is mechanistically adjacent to the NF-κB priming of NLRP3 and the dual IKKε-driven NF-κB + IRF7 crosstalk that sustains the convergent interferon–mitochondrial syndrome in SAMHD1 p.A565T haploinsufficiency; optical dissection of TLR→MyD88→NF-κB/IRF signaling could reveal druggable nodes in the IKK-NEMO complex and IRF7-metabolic amplification loop.
DOI: 10.1002/advs.202520640

Targeting the NLRP3/Caspase-1 pyroptotic pathway exacerbates insulin resistance upon exposure to nanoplastics with different surface chemistries. (from Environmental toxicology and metabolic disease; bridges to rare disease through convergent NLRP3-inflammasome-insulin-resistance axis and mitochondrial dysfunction phenocopy of SAMHD1 haploinsufficiency.)
Yao Xinxin; Cao Yu; Lin Sue; Chen Shihua; Xie Feiqin — Journal of hazardous materials 2026
Score: 6/10 | Pathways: NLRP3, mitochondrial-ROS-NF-kB, oxidative-stress-mtDNA, metabolic-dysfunction-insulin-resistance, inflammasome-pyroptosis, other

Paper demonstrates NLRP3/caspase-1 pyroptotic activation downstream of nanoplastic-induced mitochondrial dysfunction and cytosolic mtDNA accumulation in metabolic stress (hyperglycemia/insulin resistance), directly modeling the PURPLE-loop mechanism (ox-mtDNA → NLRP3) and BLUE-loop (mtDNA escape → inflammasome) operative in SAMHD1 A565T haploinsufficiency; validates NLRP3 inhibition as partial rescue strategy for metabolic phenotypes, but lacks SAMHD1, dNTPase, or dNTP-mediated mechanism, and uses exogenous environmental trigger rather than genetic haploinsufficiency.
DOI: 10.1016/j.jhazmat.2026.143078

Astilbin Alleviates Gouty Arthritis via Regulating NLRP3 Inflammasome and NF-κB Signaling Pathway: A Comprehensive Study on In Vitro and In Vivo Experimental Models. (from Rheumatology/Pharmacology (natural product anti-inflammatory); mechanism-of-action study demonstrating dual NLRP3–NF-κB inhibition in gouty arthritis model, transferable to dNTP-driven NLRP3 hyperactivation in SAMHD1-deficient states.)
Zhang Xiaoxi; Fu Gaoyang; Zhao Xinyu; Huang Yan; Li Fenfen — Nutrients 2026
Score: 6/10 | Pathways: urate-NLRP3, NLRP3, NF-kB-IKK, NF-kB-NLRP3-priming, treatment-target

Astilbin suppresses MSU-crystal–induced NLRP3 inflammasome and NF-κB signaling (P-p65, P-IKKα, P-IκBα, cleaved-caspase-1), directly targeting the GOLD pathway (dGTP → uric acid → MSU → NLRP3) and the NF-κB priming axis that sustains IL-1β autocrine amplification in SAMHD1 haploinsufficiency; relevant as a potential adjunctive therapeutic for the inflammatory arm of convergent interferon–mitochondrial syndrome in this family.
DOI: 10.3390/nu18142360

Blood transcriptome bridges orthogonal immunotypes and gut microbiome enterotypes in humans. (from Microbiome/Metabolomics)
Affaticati Fabio; Ha My K; Gehrmann Thies; De Boeck Ilke; Kuznetsova Mariia — Cell reports 2026
Score: 6/10 | Pathways: NF-kB-IKK, JAK-STAT, NLRP3, clinical-phenotype

Blood transcriptome integration identifies two distinct inflammatory profiles—interferon-driven versus NF-κB/IL-6-driven—that directly map to the divergent activation streams (BLUE interferon loop vs. PURPLE/GOLD NLRP3 loops) in SAMHD1 A565T haploinsufficiency; gut microbiota-immune axis bridging is relevant to family's reported gastrointestinal heterogeneity and immunotype stratification in interferonopathy populations.
DOI: 10.1016/j.celrep.2026.117752

Evaluation of Zebularine as a Potential DNA Methyltransferase 1 Inhibitor Associated With SAMHD1 Expression in Cancer Cells (from Oncology)
Muhammad Zeeshan Ahmed; Mahnoor Fatima; Ayesha Shahbaz; Zeeshan Mutahir — ChemistrySelect 2026
Score: 5/10 | Pathways: BIK-cancer, SAMHD1, treatment-target

Zebularine modulates SAMHD1 expression in prostate cancer cells (relevant to BIK-prostate axis and SAMHD1 as tumor suppressor in family phenotype), but mechanistic connection is via DNMT1 epigenetic silencing rather than dNTPase activity, mitochondrial dysfunction, or interferonopathy pathways central to A565T haploinsufficiency.
DOI: 10.1002/slct.73893

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

VRK3 promotes KSHV infection by suppressing the antiviral type I interferon response. (from Virology/Oncology (KSHV tropism and persistent infection pathogenesis, not immunometabolic or rare disease))
Yu Caroline J; Damania Blossom — PLoS pathogens 2026
Score: 3/10 | Pathways: IRF3, cGAS-STING, JAK-STAT, other

VRK3 suppresses IRF3 and TBK1 activation in KSHV infection, which intersects the cGAS-STING→IRF3→IFN-I axis (BLUE Loop), but lacks SAMHD1 involvement, mitochondrial pathology, dNTP metabolism, NLRP3, or direct relevance to the A565T haploinsufficiency mechanism driving the convergent interferon–mitochondrial syndrome.
DOI: 10.1371/journal.ppat.1014400


Pathway Coverage This Week

  • treatment-target: 7 papers
  • NF-kB-IKK: 7 papers
  • NLRP3: 5 papers
  • cGAS-STING: 3 papers
  • clinical-phenotype: 3 papers
  • other: 3 papers
  • urate-NLRP3: 2 papers
  • mTOR-lysosomal: 2 papers
  • BIK-cancer: 2 papers
  • NF-kB-NLRP3-priming: 2 papers
  • JAK-STAT: 2 papers
  • VDAC1: 1 papers
  • ISG15-mitophagy: 1 papers
  • POLG-mtDNA: 1 papers
  • mito-ROS-NF-kB: 1 papers
  • apoptosis-autophagy switch: 1 papers
  • mito-dNTP-transport: 1 papers
  • nucleotide-rewiring: 1 papers
  • IRF7-metabolic: 1 papers
  • mitochondrial-ROS-NF-kB: 1 papers
  • oxidative-stress-mtDNA: 1 papers
  • metabolic-dysfunction-insulin-resistance: 1 papers
  • inflammasome-pyroptosis: 1 papers
  • SAMHD1: 1 papers
  • IRF3: 1 papers

↩ Re-run 08:33 UTC | Model: claude-sonnet-5

Summary: 1 new papers | 0 high-relevance (≥7) | 1 medium (5–6) | 0 low (3–4)

🟡 Medium Relevance

Multiple Roles of G3BP1 in Regulating STING-Dependent Interferon and Cytokine Induction by Cytosolic dsDNA and HSV-1 Infection. (from Virology/cell stress biology)
Trupti Devale; Praveen Manivannan; K. Malathi — Viruses 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Details G3BP1 as a regulator of cGAS-STING signaling (STING Golgi trafficking, IFN/cytokine output) directly relevant to the BLUE loop mechanism underlying the SAMHD1 interferonopathy, though it does not involve SAMHD1 itself.
DOI: 10.3390/v18070719

SAMHD1 Research Digest — 2026-07-26

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 31 papers evaluated | 5 high-relevance (≥7) | 16 medium (5–6) | 10 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Modeling calcific aortic valve disease with engineered human valve tissues identifies SAMHD1 as a therapeutic target. (from Cardiology/bioengineering (tissue engineering and valvular calcification))
Meng Xiangfu; Zhou Qian; Zhu Zijin; Qiao Weihua; Geng Bingchuan — Biomaterials 2026
Score: 7/10 | Pathways: treatment-target, clinical-phenotype, other

This paper identifies SAMHD1 as a novel therapeutic target in calcific aortic valve disease via WGCNA-driven small-molecule inhibition, extending SAMHD1's disease relevance beyond interferonopathy into a cardiovascular/osteogenic context pertinent to potential cardiac phenotypes in the family.
DOI: 10.1016/j.biomaterials.2026.124432

The mitochondrial DNA signal in rheumatoid arthritis: From metabolic victim to inflammatory driver. (from Rheumatology)
Zhang Ruoyi; Song Zhijie; Xin Qimeng; Xing Wenbin; Zhang Wenlan — Biochemical and biophysical research communications 2026
Score: 7/10 | Pathways: cGAS-STING, NLRP3, POLG-mtDNA, clinical-phenotype, treatment-target

Reviews the mtDNA damage-release-cGAS/STING-NLRP3 axis driving RA inflammation, mechanistically parallel to the purple/blue loops in the SAMHD1 syndrome and directly relevant to the family's rheumatoid arthritis phenotype.
DOI: 10.1016/j.bbrc.2026.154304

Case of Aicardi-Goutières syndrome diagnosed in adulthood on whole-genome sequencing. (from Neurology/Genetics)
Cobb Lewis; Kumar Jayant; Roy Amit; Walsh Sarah; Sheerin Una-Marie — BMJ neurology open 2026
Score: 7/10 | Pathways: AGS-spectrum, cGAS-STING, JAK-STAT, treatment-target, clinical-phenotype

This adult-diagnosed ADAR-related AGS case with atypical presentation, cardiac calcification, and baricitinib consideration directly parallels the type I interferonopathy spectrum and JAK inhibitor treatment strategy relevant to SAMHD1-driven disease.
DOI: 10.1136/bmjno-2025-001407

HTLV-1 Tax induces PINK1-PRKN/parkin-dependent mitophagy to mitigate activation of the CGAS-STING1 pathway. (from Virology/hematology (HTLV-1-associated leukemia and neuroinflammatory disease))
Mohanty Suchitra; Suklabaidya Sujit; Mnatsakanyan Nelli; Jacobson Steven; Harhaj — Autophagy 2026
Score: 7/10 | Pathways: cGAS-STING, ISG15-mitophagy, NF-kB-IKK, treatment-target

This paper demonstrates PINK1-PRKN-dependent mitophagy (via NEMO/IKK interaction) suppressing cGAS-STING1-driven type I interferon activation in a viral infection context, directly paralleling the mitophagy-block/IFN-I-amplification mechanism central to the SAMHD1 syndrome model (RED/BLUE loops) even though the driver here is HTLV-1 Tax rather than SAMHD1 dysfunction.
DOI: 10.1080/15548627.2026.2707897

Type I interferonopathies: 15 years after the concept-news and views. (from Rheumatology)
S. Khaldi-Plassart; I. Melki; M. Frémond — Current opinion in rheumatology 2026
Score: 7/10 | Pathways: cGAS-STING, AGS-spectrum, treatment-target, clinical-phenotype, JAK-STAT

This review covers type I interferonopathy mechanisms (STING/IFNAR signaling, TLR pathways, clinical penetrance variability, JAK inhibitor therapeutics) directly relevant to the SAMHD1-driven IFN-I overproduction and AGS-spectrum disorder underlying the family syndrome, though it does not address SAMHD1 specifically.
DOI: 10.1097/BOR.0000000000001179

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Fibroblast S1PR2 Amplifies NLRP3 Inflammasome Activation Under Pressure Overload. (from Cardiology)
Zhou Caixia; Liu Zhihao; Wang Zhiru; Cui Zekun; Wang Qian — Hypertension (Dallas, Tex. : 1979) 2026
Score: 6/10 | Pathways: NLRP3, mito-ROS-NF-kB, treatment-target

Demonstrates mitochondrial damage (DRP1 fission, mitophagy suppression) driving mtDNA leakage and NLRP3 activation, mechanistically parallel to the SAMHD1 mitochondrial-inflammasome axis though in cardiac fibroblasts rather than SAMHD1-deficient immune cells.
DOI: 10.1161/HYPERTENSIONAHA.126.27475

Isoalantolactone targets NLRP3 to disrupt NLRP3-NEK7 interaction and suppress inflammasome activation. (from pharmacology/drug discovery)
Shi Yuanfang; Zhu Xiaoyun; Sun Meng; Yang Yang; Lin Siwei — Biochemical pharmacology 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, treatment-target

This paper identifies a small-molecule NLRP3 inhibitor effective against MSU-induced gout and MASLD, directly relevant to the GOLD pathway (dGTP→uric acid→MSU→NLRP3) and offering a potential therapeutic candidate for the syndrome's inflammasome-driven pathology.
DOI: 10.1016/j.bcp.2026.118165

Interferon-related gene expression defines disease activity, organ involvement and treatment response in juvenile dermatomyositis. (from Pediatric rheumatology (juvenile dermatomyositis))
Codes-Méndez Helena; Cuyx Senne; Syntakas Aris E; Barmpakou Afroditi; Moraitis E — Rheumatology (Oxford, England) 2026
Score: 6/10 | Pathways: JAK-STAT, treatment-target, clinical-phenotype

Demonstrates type-I interferon-related gene expression (ISGs, IFI27, IFI44L, RSAD2) as biomarker of disease activity and JAK inhibitor (baricitinib) response, directly reinforcing the IFN-I/JAK-STAT arm of the interferonopathy mechanism relevant to SAMHD1 pathway and treatment translation, though not SAMHD1-specific.
DOI: 10.1093/rheumatology/keag384

Glycerol-3-Phosphate Attenuates Hypoxic-Ischemic Brain Injury via Modulation of Microglia-Mediated Neuroinflammation. (from Neurology/perinatal neonatology)
Qin Dani; Lei Yong; Le Meini; Cheng Mengke; Zhao Yingmin — Neurochemical research 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target, mito-ROS-NF-kB

Demonstrates cGAS-STING-TBK1-NF-kB axis driving microglial neuroinflammation and mitochondrial dysfunction, directly relevant to the same core pathway implicated in the SAMHD1 A565T interferon-mitochondrial syndrome, with therapeutic implications for neuroinflammatory phenotypes seen in the family (AuDHD, ME/CFS-like fatigue).
DOI: 10.1007/s11064-026-04848-x

Aspirin Inhibits the cGAS-STING Signaling Pathway to Ameliorate the Development of Aortic Aneurysm and Dissection. (from Vascular surgery/cardiology (aortic aneurysm and dissection))
Zeng Yi-Fan; Wang Qiu-Guo; Qi Zhen; Li Jing-Yu; Duan Zhi-Cheng — Arteriosclerosis, thrombosis, and vascular biology 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Demonstrates a novel cGAS-STING axis (via cGAS acetylation) driving mitochondrial/ferroptotic vascular pathology and its pharmacological inhibition by aspirin, directly relevant to the Blue loop mechanism though in a cardiovascular rather than immune context.
DOI: 10.1161/ATVBAHA.126.324930

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells. (from Oncology (esophageal squamous cell carcinoma immunotherapy))
Chen Linyan; Feng Tang; Zhou Jianfeng; Zeng Hao; Lai Yutian — Cancer research 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, other

This paper demonstrates TFAM deficiency in dendritic cells activating the STING-TBK1-IRF3 pathway to promote anti-tumor immunity, directly relevant to the mitochondrial-cGAS-STING-IFN-I axis central to the SAMHD1 mechanism though in an oncologic rather than interferonopathy context.
DOI: 10.1158/0008-5472.CAN-25-4738

Stub1 promotes chaperone-mediated autophagy to suppress antiviral immunity. (from Virology/cell biology (autophagy regulation))
Liu Hongyang; Huang Li; Weng Changjiang — Autophagy 2026
Score: 6/10 | Pathways: cGAS-STING, JAK-STAT, treatment-target

This paper describes a novel TBK1 degradation pathway (CMA via Stub1) that directly regulates the cGAS-STING-TBK1-IFN-I axis central to the SAMHD1 mechanism, relevant to interferonopathy modulation though not SAMHD1-specific.
DOI: 10.1080/15548627.2026.2667376

Dual-regulation of mitophagy and cytosolic mtDNA-induced inflammation for the treatment of inflammatory bone loss. (from orthopedics/bone regeneration)
Zheng Kaiwen; Che Benchi; Cui Yongzhi; Yang Han; Xiang Yu — 2026
Score: 6/10 | Pathways: cGAS-STING, ISG15-mitophagy, treatment-target, clinical-phenotype

Directly models the mtDNA-cGAS-STING-inflammation-mitophagy (PINK1) axis central to the BLUE/RED streams and demonstrates a dual STING/PINK1 exosome therapeutic, relevant to osteoporosis noted in family phenotype tracking though not SAMHD1-specific.
DOI: 10.1016/j.freeradbiomed.2026.07.031

Tumor microenvironment-responsive manganese nanoplatform amplifies cGAS-STING via metabolic-metal synergy for immunotherapy. (from Oncology/nanomedicine)
Zhou Yanlin; Wu Ziyi; Zheng Tao; Luo Shunhong; Zhang Lu — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Demonstrates mitochondrial fragmentation-driven mtDNA leakage activating cGAS-STING (mirroring the BLUE/VDAC1 loop) in an oncology nanomedicine context, offering mechanistic and therapeutic parallels though not SAMHD1-specific.
DOI: 10.1016/j.jconrel.2026.115197

Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis. (from Orthopedics/Nanomedicine)
Li Tiancheng; Zheng Ao; Zhu Cheng; Li Yixin; Yang Zitong — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Demonstrates a nanozyme therapeutic that restores mitophagy and blocks mtDNA-driven cGAS/STING inflammation, directly reinforcing the disease model's Loop A mechanism though in an unrelated joint disease context.
DOI: 10.1016/j.bioactmat.2026.07.010

Engineering-Modulated Molybdenum Enzymes Strategy for Tumor-Specific Metabolic-Immunotherapy. (from oncology/nanomedicine)
Pan Xiaoxiao; Pei Zifan; Wu Jie; Jiang Nan; Li Qian — 2026
Score: 6/10 | Pathways: cGAS-STING, urate-NLRP3, treatment-target

This oncology nanomedicine paper demonstrates mtDNA release activating cGAS-STING and purine metabolism driving uric acid elevation as an immune activator, mechanistically paralleling the PURPLE/GOLD and BLUE streams (dGTP-uric acid-MSU-NLRP3 and mtDNA-cGAS-STING) in the SAMHD1 syndrome despite being applied in a cancer immunotherapy context.
DOI: 10.1002/advs.76726

Phase-dependent dynamics of circulating cell-free mitochondrial DNA reflect distinct immunometabolic states (from Tropical medicine/infectious disease and pediatric cardiac surgery biomarker research)
Karen Alessandra Rodrigues; Emilly Henrique dos Santos; Gabriel Acca Barreira; M — Revista do Instituto de Medicina Tropical de São Paulo 2026
Score: 6/10 | Pathways: VDAC1, NLRP3, treatment-target, clinical-phenotype

Circulating cell-free mtDNA as a DAMP driving innate immune activation is directly relevant to the BLUE/PURPLE mitochondrial escape and NLRP3 activation loops central to the SAMHD1 interferon-mitochondrial syndrome, though it does not address SAMHD1 itself.
DOI: 10.1590/s1678-9946202668048

Severe Antenatal Presentation of a Novel Dnase2 Mutation in a Preterm Omani Neonate: Expanding the Clinical Spectrum of an Ultra-Rare Interferonopathy (from Neonatology/Pediatric Genetics)
Ruqaiya Al Jashmi; Marya Al Barumi; S. Al Abrawi; Alyaa Al Mughairy; Aiman Al Ja — Cureus 2026
Score: 6/10 | Pathways: cGAS-STING, JAK-STAT, AGS-spectrum, clinical-phenotype, pregnancy-fetal, treatment-target

DNASE2 deficiency is a type I interferonopathy in the same AGS-spectrum family of diseases as SAMHD1 mutations, sharing cGAS-STING-driven IFN-I pathology and JAK inhibitor responsiveness, with fetal/neonatal presentation relevant to the pregnancy-interferonopathy phenotype tracking axis.
DOI: 10.7759/cureus.111043

Sex-specific differences of amlexanox in a mouse model for atherosclerosis and MASLD. (from Cardiometabolic/hepatology research on IKKε inhibition)
Mungo Eleonora; Haß Michelle; Benning Denis; Schmid Tobias; Kuntschar Silvia — Molecular metabolism 2026
Score: 5/10 | Pathways: NF-kB-IKK, clinical-phenotype

IKKε (a kinase explicitly named in the NF-κB crosstalk mechanism as dual NF-κB/IRF3 activator) is targeted pharmacologically here, showing sex-specific metabolic/inflammatory effects on MASLD and atherosclerosis, relevant background to the IKKβ/IKKε axis but without SAMHD1 or interferon pathway data.
DOI: 10.1016/j.molmet.2026.102426

Editing Around the Target: Epitope Engineering to Protect Stem Cell Grafts. (from Gene therapy/hematology-oncology)
Baek Joanne; Casirati Gabriele; Genovese Pietro; Gill Saar I — Blood advances 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery

Reviews base/prime editing epitope engineering in HSPCs, relevant as a generic delivery/correction platform potentially applicable to correcting SAMHD1 missense variants in myeloid cells but not disease-specific.
DOI: 10.1182/bloodadvances.2025018227

Efficient CRISPR/Cas9-mediated homology independent sequence replacement in vivo and non-dividing primary cells (from genome editing / gene therapy engineering)
Dang Tu Ngoc; Roman Alexandra; Zimmer Anja; Lebedin Mikhail; Bahry Ella — preprint (preprint) 2026
Score: 5/10 | Pathways: gene-therapy-delivery, prime-editing

This paper describes a novel homology-independent CRISPR/Cas9 sequence replacement platform (REPLACE) using eVLP/AAV delivery in non-dividing cells, relevant as a general gene correction strategy applicable to correcting missense variants like SAMHD1 A565T though not directly tested on it.
DOI: 10.64898/2026.07.24.740048

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

Alopecia areata: Mechanisms, targeted therapies, and translational challenges. (from Dermatology)
Kumar Virender; Sahoo Saurabh; Kumar Pawan — Current opinion in pharmacology 2026
Score: 4/10 | Pathways: JAK-STAT, treatment-target

AA pathogenesis and JAK inhibitor therapy (baricitinib) overlap mechanistically with the IFN-I/JAK-STAT axis relevant to SAMHD1 interferonopathy, but the paper is otherwise unrelated to SAMHD1 or mitochondrial-inflammasome mechanisms.
DOI: 10.1016/j.coph.2026.102635

Gene therapy approaches for inborn errors of immunity: from bench to bedside. (from gene therapy/genetic medicine)
Dara Jasmeen; Booth Claire — Expert opinion on biological therapy 2026
Score: 4/10 | Pathways: gene-therapy-delivery

General review of gene therapy for inborn errors of immunity (retroviral, lentiviral, CRISPR, base/prime editing) provides background relevance to future correction strategies for SAMHD1 variants but has no disease-specific or mechanistic content.
DOI: 10.1080/14712598.2026.2710870

Mitochondrial stress-induced cuproptosis: a metabolic bridge to reprogramming the GBM immune microenvironment. (from Oncology (neuro-oncology/GBM immunotherapy))
Li Wenyang; Lv Yaqing; Wang Guanrong; Lan Xiaolei; Ren Leina — 2026
Score: 4/10 | Pathways: cGAS-STING, other

Discusses mtDNA release triggering cGAS-STING/type I IFN in GBM cuproptosis context, sharing a core mechanistic node but unrelated to SAMHD1 dNTPase biology or the family phenotype spectrum.
DOI: 10.1007/s13402-026-01254-x

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation (from Neurology/gene therapy)
Tianshan Ji; Yuan Zhang; Jinyi Zhao; Yi Lu; Chengkun Wang — Neuroprotection 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

General review of prime editing for neuropsychiatric monogenic disorders offers relevant delivery/technology context but no direct SAMHD1, immune, or mitochondrial pathway content and focuses on neurons rather than myeloid/immune cells.
DOI: 10.1002/nep3.70041

A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. (from oncology/cancer immunotherapy)
Zhang Wenbo; Ni Xinrui; Zhuo Luoyi; Liu Jiangrui; Yang Guang — Cell reports. Medicine 2026
Score: 3/10 | Pathways: cGAS-STING, treatment-target

This oncology immunotherapy paper touches TBK1-IRF3-type I interferon axis (relevant pathway component) but in a tumor vaccine/anti-PD-1 context unrelated to SAMHD1 haploinsufficiency or the family's interferonopathy syndrome.
DOI: 10.1016/j.xcrm.2026.102932

Gene/Genome Editing in Cardiovascular Biology and Disease. (from Cardiology/gene therapy)
Verma Tushar; Singh Ravi Pratap; Chaudhary Mahima; Sharma Pramod Kumar; Kumar Dh — Current gene therapy 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery

This is a general cardiovascular gene-editing review with no connection to SAMHD1, interferon-mitochondrial mechanisms, or myeloid/immune cell editing relevant to the family syndrome.
DOI: 10.2174/0115665232453929260206091608

Mitochondrial Communication Networks in the Bone Microenvironment: From the Maintenance of Homeostasis to Translational Interventions for Bone Diseases. (from Orthopedics/bone biology)
Wang Wentao; Wang Kun; Wang Wenjing; Mu Xuan; Cheng Zhiquan — 2026
Score: 3/10 | Pathways: cGAS-STING, other

Bone microenvironment mitochondrial transfer review touches cGAS-STING/mtDNA release but is focused on osteoporosis/osteoarthritis biology largely tangential to SAMHD1 interferonopathy mechanism.
DOI: 10.1007/s12015-026-11190-w

An Insight into the cGAS-STING Pathway Modulation by Metal Complexes to Initiate Immunogenic Cell Death in Cancer. (from medicinal chemistry/oncology)
Shilpendu Ghosh; Sujato Mukherjee; Arindam Mukherjee — Journal of medicinal chemistry 2026
Score: 3/10 | Pathways: cGAS-STING, treatment-target

Discusses cGAS-STING pathway modulation via metal complexes for cancer immunotherapy, mechanistically relevant to Loop A but focused on oncology drug design rather than SAMHD1 or the family syndrome.
DOI: 10.1021/acs.jmedchem.6c00727

Caloric restriction enhances radiosensitivity of colorectal tumors through the cGAS-STING pathway activation. (from Oncology/radiation biology)
Li-Li Zhang; Li-Qiang Qin; Li Ding; Wenyue Shan; Yu Zhao — Cancer & metabolism 2026
Score: 3/10 | Pathways: cGAS-STING

This paper studies cGAS-STING pathway activation via caloric restriction to enhance radiosensitivity in colorectal cancer, sharing a core pathway but in an oncology/radiotherapy context unrelated to SAMHD1 dysfunction, mitochondrial dNTP dysregulation, or the interferonopathy syndrome described.
DOI: 10.1186/s40170-026-00449-y

From convergence to an iterative Optimization-Circumvention-Collapse framework in CRISPR bioengineering (from bioengineering/education)
Federico Filippone-Thaulero — Journal of High School Science 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery

General theoretical review of CRISPR/base/prime editing trade-offs from a high school science journal, with no immune/myeloid cell specificity or SAMHD1 relevance beyond generic gene-editing correction strategy context.
DOI: 10.64336/001c.165176


Pathway Coverage This Week

  • treatment-target: 21 papers
  • cGAS-STING: 18 papers
  • clinical-phenotype: 9 papers
  • JAK-STAT: 6 papers
  • gene-therapy-delivery: 6 papers
  • prime-editing: 5 papers
  • other: 4 papers
  • NLRP3: 4 papers
  • AGS-spectrum: 3 papers
  • NF-kB-IKK: 3 papers
  • ISG15-mitophagy: 2 papers
  • mito-ROS-NF-kB: 2 papers
  • urate-NLRP3: 2 papers
  • POLG-mtDNA: 1 papers
  • VDAC1: 1 papers
  • pregnancy-fetal: 1 papers

SAMHD1 Research Digest — 2026-07-19

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 7 papers evaluated | 0 high-relevance (≥7) | 3 medium (5–6) | 4 low (3–4) | 0 scored <3


🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Chirality-dependent toxicity decoupling: Discovery of a resibufogenin-based L-configured STING inhibitor with superior therapeutic profile for ulcerative colitis. (from medicinal chemistry/gastroenterology (ulcerative colitis drug discovery))
Zhuang Jia-Hua; Zhang Qiu-Heng; Zhou Si-Yu; Wen Yuting; Li Yiming — European journal of medicinal chemistry 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Novel STING inhibitor targeting the STING-TBK1-IRF3-IL-1beta/IL-6/TNF-alpha axis directly relevant to the BLUE loop IFN-I pathway central to this interferonopathy syndrome, though not disease-specific.
DOI: 10.1016/j.ejmech.2026.119146

Biallelic mutations in SUPV3L1 cause a variable leukodystrophy due to impaired mitochondrial degradosome function (from Neurology/neurogenetics (leukodystrophy))
L. Green; Noémie Hamilton; M. Elpidorou; R. Maroofian; Maha S. Zaki — Research Square 2026
Score: 6/10 | Pathways: cGAS-STING, JAK-STAT, AGS-spectrum, clinical-phenotype, other

Describes a distinct mitochondrial nucleic-acid-sensing disorder (mitochondrial dsRNA degradosome dysfunction) converging on type I interferon activation via dysplastic microglia, mechanistically analogous though not identical to the SAMHD1-driven interferonopathy loop (Blue/Red streams).
DOI: 10.21203/rs.3.rs-4356120/v2

Clinical phenotype and laboratory markers in patients affected by haploinsufficiency of A20 (HA20): a case series from two Italian centres (from Rheumatology/pediatric autoinflammatory disease)
Laura De Nardi; Silvia Federici; Eleonora De Martino; Camilla Celani; Martina Gi — RMD Open 2026
Score: 5/10 | Pathways: NF-kB-IKK, clinical-phenotype, AGS-spectrum

A20 (TNFAIP3) haploinsufficiency is a distinct NF-kB-regulatory autoinflammatory disease showing an analogous interferon-signature/NF-kB-driven phenotype with neuropsychiatric comorbidity, offering indirect mechanistic and biomarker parallels to the SAMHD1 interferonopathy-NF-kB axis but no direct SAMHD1 or mitochondrial dNTP data.
DOI: 10.1136/rmdopen-2026-006763

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS–STING pathway: mechanisms, challenges, and combination therapy strategies (from Oncology/radiotherapy)
Yongze He; Xianhu Zeng; Qianyi Liu; Linsen Zhou; Ying Tang — Molecular Cancer 2026
Score: 4/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target

This oncology-focused review discusses cGAS-STING and NF-κB activation via radiotherapy-induced DNA damage in tumors, mechanistically overlapping with the Blue loop but in a distinct clinical context (cancer immunotherapy) not directly tied to SAMHD1 or the interferon-mitochondrial syndrome.
DOI: 10.1186/s12943-026-02634-5

Orally delivered Perilla frutescens-derived nanovesicles regulate the gut-kidney biointerface to attenuate hyperuricemia-associated renal injury. (from Nephrology/gut-kidney axis nutraceutical delivery)
Yang Zhuohang; Yang Siqi; Ran Yi; Zhang Tangqing; Zhang Fen — Colloids and surfaces. B, Biointerfaces 2026
Score: 3/10 | Pathways: urate-NLRP3

The paper touches on the GOLD-stream urate-NLRP3 axis via hyperuricemia-induced renal NLRP3 inflammation, but is a nanovesicle/nephrology-nutraceutical study unrelated to SAMHD1 or the broader interferon-mitochondrial mechanism.
DOI: 10.1016/j.colsurfb.2026.115995

Precision prime editing of TP53 mutations for functional tumor suppression in colorectal cancer. (from Oncology/genome engineering)
Azhar Md; Malviya Rishabha; Chandra Phool; Sridhar Sathvik Belagodu; Shareef Jav — Biochemical and biophysical research communications 2026
Score: 3/10 | Pathways: prime-editing

Discusses prime editing technology for TP53 in colorectal cancer, offering only generic technical relevance to gene correction methods rather than SAMHD1 or immune-mitochondrial mechanisms.
DOI: 10.1016/j.bbrc.2026.154311

Oxoisoaporphine Alkaloid Piano-Stool Arene Ruthenium(II) Derivative: A cGAS-STING-Mediated Chemoimmunotherapy Inducer that Acts as a Dual Catalytic Inhibitor of Topoisomerase I/II. (from Medicinal chemistry/oncology drug design)
Liang-Mei Yang; Yuan Lu; Matthew S. Levine; Xueqian Wang; Ya-Qian Shi — Journal of the American Chemical Society 2026
Score: 3/10 | Pathways: cGAS-STING

Describes a ruthenium-based chemotherapeutic that activates cGAS-STING for oncologic immunotherapy, sharing a pathway node but with no connection to SAMHD1, mitochondrial dNTP biology, or the family's clinical phenotypes.
DOI: 10.1021/jacs.6c01872


Pathway Coverage This Week

  • cGAS-STING: 4 papers
  • treatment-target: 2 papers
  • AGS-spectrum: 2 papers
  • clinical-phenotype: 2 papers
  • NF-kB-IKK: 2 papers
  • JAK-STAT: 1 papers
  • other: 1 papers
  • urate-NLRP3: 1 papers
  • prime-editing: 1 papers

SAMHD1 Research Digest — 2026-07-18

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 35 papers evaluated | 6 high-relevance (≥7) | 17 medium (5–6) | 12 low (3–4) | 0 scored <3


🔴 High Relevance (Score 7–10)

Auto-added to Zotero (threshold ≥6)

Transition Metal Activation Reframes SAMHD1 Regulation. (from biochemistry/metalloenzyme spectroscopy)
Calderone Logan A; Gizzi Anthony; Pinninti Soumika; Stivers James T; Pandelia Ma — ACS chemical biology 2026
Score: 8/10 | Pathways: dNTPase, treatment-target

This paper directly characterizes the metal cofactor requirements (iron/manganese) for SAMHD1's dNTPase catalytic activity, providing fundamental mechanistic insight into the enzyme whose partial loss-of-function (as in A565T) drives the entire dNTP pool expansion cascade underlying this syndrome.
DOI: 10.1021/acschembio.6c00438

Mitochondrial dynamics and metabolic regulation in cellular inflammation: From mechanisms to precision therapeutics. (from Pharmacology/mitochondrial cell biology)
Park Woo Hyun — Pharmacology & therapeutics 2026
Score: 8/10 | Pathways: NLRP3, cGAS-STING, mito-dNTP-transport, nucleotide-rewiring, treatment-target, VDAC1

Directly engages ox-mtDNA/cGAS-STING/NLRP3 activation via mitochondrial dynamics and explicitly discusses the YME1L-SLC25A33 pyrimidine-imbalance axis, closely paralleling the PNC1/2 nucleotide-carrier mechanism central to the disease model.
DOI: 10.1016/j.pharmthera.2026.109086

MGMT deficiency augments STING-mediated inflammatory responses accompanied by metabolic alterations in macrophages. (from DNA repair biology / cancer genetics)
Kongkavitoon Pornrat; Boonmee Atsadang; Pattarakankul Thitiporn; Wongprom Benjaw — Scientific reports 2026
Score: 7/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target, other

Demonstrates that DNA repair deficiency (MGMT) amplifies STING-TBK1-IRF3 signaling and mitochondrial oxidative metabolism in macrophages, directly relevant to the interferon-mitochondrial crosstalk (cGAS-STING/IRF3, mitochondrial respiration, DNA damage) central to the SAMHD1 syndrome's BLUE/RED loops.
DOI: 10.1038/s41598-026-62431-4

The Development of UM-232, a Covalent STING Antagonist. (from Medicinal chemistry/drug discovery)
Barasa Leonard; DeOrsey Leo; O'Reilly Maeve D; Cahill Sara E; Choudhary Shruti — ACS medicinal chemistry letters 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target

Describes a novel covalent STING antagonist directly targeting the cGAS-STING axis (Loop A) that drives the IFN-I overproduction central to this SAMHD1 haploinsufficiency syndrome, offering potential therapeutic relevance despite no direct SAMHD1 data.
DOI: 10.1021/acsmedchemlett.6c00114

Electroacupuncture alleviates spinal cord injury by regulating M2-like polarization of myeloid cells through CMPK2/NLRP3 inflammasome inhibition. (from Neurology/Rehabilitation (spinal cord injury, acupuncture))
Zhang Kai; Zhang Mengru; Chen Yi; Ni Ziao; Huang Yi — International immunopharmacology 2026
Score: 7/10 | Pathways: NLRP3, mito-dNTp-transport, nucleotide-rewiring, treatment-target

This paper directly implicates CMPK2 as a regulator of NLRP3 inflammasome activation and myeloid polarization, mechanistically connecting the CMPK2-dependent mitochondrial dNTP salvage pathway (a key node in the SAMHD1/PNC1/PNC2 nucleotide-rewiring model) to NLRP3-driven neuroinflammation, offering a non-obvious cross-context validation of the CMPK2/NLRP3 axis relevant to the SAMHD1 haploinsufficiency mechanism.
DOI: 10.1016/j.intimp.2026.116989

Mitochondrial DNA efflux as a potential amplifier of systemic inflammatory network rewiring in heart failure with preserved ejection fraction (from Cardiology)
Xingwei Zhao; Shengyu Huang; Qiuling Li; Yang Yu; Chunxiang Zhang — Frontiers in Immunology 2026
Score: 7/10 | Pathways: cGAS-STING, NLRP3, NF-kB-NLRP3-priming, POLG-mtDNA, clinical-phenotype, treatment-target

Describes mtDNA release activating cGAS-STING/TLR9 and NLRP3 inflammasome as a cross-organ inflammatory amplifier, directly paralleling the BLUE/Loop A and NLRP3 priming mechanisms in the SAMHD1 syndrome model though in a cardiology (HFpEF) context rather than SAMHD1-driven disease.
DOI: 10.3389/fimmu.2026.1866184

🟡 Medium Relevance (Score 5–6)

Score ≥6 auto-added to Zotero; lower scores: review manually

Niflumic acid suppresses NLRP3 inflammasome activation by limiting chloride efflux and mitochondrial ROS production. (from pharmacology/drug repurposing)
Li Yuanhao; Xie Qianqian; Sun Tianyin; Lu Jiwei; Li Mengmeng — Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026
Score: 6/10 | Pathways: NLRP3, mito-ROS-NF-kB, urate-NLRP3, treatment-target

Paper details a mitochondrial ROS-dependent NLRP3 activation mechanism (via chloride efflux/TMEM16F) and MSU-crystal-driven inflammasome activation, both directly paralleling the GOLD (urate-NLRP3) and mito-ROS-NF-kB routes in the disease model, with NFA representing a potential adjunct NLRP3-targeting therapeutic.
DOI: 10.1007/s00011-026-02328-0

Targeting CCDC90B restores intestinal stem cell function under hyperuricemic stress. (from Gastroenterology/stem cell biology)
Peng Xiuying; Li Moxuan; Zeng Kaixuan; Lv Wantong; Huang Shuai — Stem cell reports 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, treatment-target

Demonstrates the GOLD-stream mechanism (uric acid → mitochondrial ROS → NLRP3 activation) directly, relevant to the family's SAMHD1-driven dGTP/purine catabolism route to inflammasome activation, albeit in intestinal stem cells rather than immune cells.
DOI: 10.1016/j.stemcr.2026.102970

Ring-finger protein 5 protects against diabetic kidney disease by targeting and degrading STING. (from Nephrology/Endocrinology (diabetic kidney disease))
Dong Chunping; Sun Yan; Li Hui; Qiao Yuan; Gao Shan — Pathology, research and practice 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target

Demonstrates RNF5-mediated ubiquitin degradation of STING suppressing TBK1/IRF3/NF-kB activation and fibrosis in diabetic kidney disease, offering a plausible downstream therapeutic node for the STING/NF-kB arm of the interferon-mitochondrial syndrome despite being in a different clinical context (nephrology/diabetes).
DOI: 10.1016/j.prp.2026.156618

Targeting MDA5-Mediated Interferon Responses in Type 1 Diabetes: Structural Insights, Mechanism, and Potential Therapeutic Approaches. (from Endocrinology (type 1 diabetes autoimmunity))
Iwaloye Opeoluwa F; Mathews Clayton E; Li Danmeng — Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2026
Score: 6/10 | Pathways: IRF7-metabolic, NF-kB-IKK, treatment-target, clinical-phenotype

MDA5/IFIH1-driven type I interferon signaling via TBK1/IKKε-IRF and NF-κB converges mechanistically with the SAMHD1 cGAS-STING/NF-κB interferonopathy axis and shares therapeutic logic (JAK/IFN pathway targeting) relevant to autoimmune comorbidities in the family phenotype spectrum.
DOI: 10.1177/10799907261467555

Senegenin mitigates neuroinflammation, pyroptosis, and apoptosis in cerebral ischemia via inhibiting STING and downstream inflammatory pathway. (from neurology/stroke pharmacology)
Chauhan Chandan; Kaundal Ravinder K — European journal of pharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, NF-kB-IKK, treatment-target

Demonstrates pharmacological STING-TBK1-IRF3 and NF-κB/NLRP3 pathway inhibition reducing pyroptosis/apoptosis in a disease model, directly relevant to the core Loop A/B mechanism though in an unrelated ischemic stroke context rather than SAMHD1-driven interferonopathy.
DOI: 10.1016/j.ejphar.2026.179147

Dietary riboflavin blocks the cGAS-STING pathway to curb hypoxia-induced hepatic inflammation in sub-adult grass carp (Ctenopharyngodon idella). (from veterinary/aquaculture nutrition science)
Zhong Lin; Feng Lin; Wu Pei; Jiang Weidan; Zhang Hongyun — Animal nutrition (Zhongguo xu mu shou yi xue hui) 2026
Score: 6/10 | Pathways: cGAS-STING, VDAC1, NF-kB-IKK, mito-ROS-NF-kB, treatment-target

This fish study demonstrates VDAC1/mtDNA-driven cGAS-STING-TBK1-IRF3/NF-kB (p-P65) activation causing hepatic inflammation under hypoxia, mirroring the BLUE loop and NF-kB crosstalk mechanisms in the SAMHD1 syndrome, with riboflavin as a mitochondrial-protective therapeutic lever relevant to treatment strategies.
DOI: 10.1016/j.aninu.2026.01.012

Reduced myocardial NRG-1/ErbB4 signaling is associated with STING-linked macrophage pyroptotic signaling in sepsis-induced cardiac injury. (from Cardiology/sepsis)
Wei Yanian; Wang QianWen; Shen Cheng; Pan Xia; Kang Wen — International immunopharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, NF-kB-IKK, treatment-target

This paper demonstrates cGAS-STING-TBK1-IRF3/NF-kB signaling driving macrophage pyroptosis (NLRP3, caspase-1, GSDMD-N) in cardiac injury, directly relevant to the interferon-inflammasome axis and cardiac phenotype seen in the SAMHD1 family, though it lacks any SAMHD1 connection.
DOI: 10.1016/j.intimp.2026.117044

LKB1/ AMPK deficiency aggravates mitochondrial DNA leakage via mTOR-dependent mitophagy damage in liver injury sensitized by trichloroethylene. (from Occupational/environmental toxicology and hepatology)
Zhu Lifu; Wan Chenghuan; Li Zijun; Fan Xuan; Liu Dongsheng — 2026
Score: 6/10 | Pathways: cGAS-STING, mTOR-lysosomal, treatment-target

Demonstrates mitophagy failure leading to mtDNA leakage and cGAS-STING-driven inflammation via LKB1/AMPK/mTOR axis, mechanistically parallel to the mitochondrial-interferon convergence in the SAMHD1 syndrome despite a different toxicological trigger.
DOI: 10.1016/j.cbi.2026.112261

Microglial mitophagy as an immunometabolic checkpoint in alzheimer's disease: linking mitochondrial quality control to neuroinflammation. (from Neurodegeneration/neuroimmunology)
Zou Mingyue; Zhao Tengyu; Wu Weidong; Zhang Jian; Pan Pengyu — 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, ISG15-mitophagy, mTOR-lysosomal, treatment-target

Reviews microglial mitophagy failure driving mtDNA/mtROS-triggered cGAS-STING and NLRP3 activation with TBK1 signaling, mechanistically parallel to the mitochondrial-quality-control/interferon-inflammasome axis central to the SAMHD1 syndrome, though disease context is Alzheimer's rather than SAMHD1.
DOI: 10.1186/s12974-026-03946-5

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart (from Cardio-oncology/pharmacology)
Kelsey H. Fisher-Wellman; Richard D. Lutze; Logan G. Kirkland; J. Beak; Mansi Go — Science Advances 2026
Score: 6/10 | Pathways: cGAS-STING, mito-ROS-NF-kB, treatment-target

Demonstrates mitochondrial DNA damage triggering cGAS-STING innate immune activation via mitochondrial dysfunction and ETC impairment, directly paralleling the BLUE/Loop A mechanism in the SAMHD1 syndrome, though in a drug-cardiotoxicity rather than SAMHD1 context.
DOI: 10.1126/sciadv.aeb2695

The mitochondrial logic of inflammaging: how energy imbalance drives fibroblast SASP and tissue-specific aging (from Geroscience/periodontology)
Yu Huan; Qiqi Wang; Rongkaixuan Fang; Yue Sun; Meiya Suo — Frontiers in Immunology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, NF-kB-IKK, mito-ROS-NF-kB, treatment-target

This paper reviews mitochondrial danger signal (mtROS/mtDNA)-driven cGAS-STING/NLRP3/NF-kB convergence in cellular senescence, mechanistically paralleling the SAMHD1 syndrome's Loop A/B and NF-kB crosstalk axes though in a general aging/periodontal context without SAMHD1 involvement.
DOI: 10.3389/fimmu.2026.1881243

How Redox Modulation May Help Prevent Age-Related Decline (from nutrition/geroscience)
M. Amirova — PHYTONutrients 2026
Score: 6/10 | Pathways: NLRP3, cGAS-STING, NF-kB-IKK, NF-kB-NLRP3-priming, mito-ROS-NF-kB, treatment-target

General review of mitochondrial DAMP-driven cGAS-STING/NLRP3/NF-kB inflammaging and NRF2 antioxidant modulation overlaps mechanistically with the IFN-mitochondrial-inflammasome axis but lacks SAMHD1-specific or dNTP pathway data.
DOI: 10.62368/pn.v5i1.71

Biallelic mutations in SUPV3L1 cause a variable leukodystrophy due to impaired mitochondrial degradosome function (from Neurology/leukodystrophy genetics)
L. Green; Noémie Hamilton; M. Elpidorou; R. Maroofian; Maha S. Zaki — Research Square 2026
Score: 6/10 | Pathways: cGAS-STING, AGS-spectrum, clinical-phenotype

Mitochondrial dsRNA degradosome dysfunction driving type I interferon activation via microglia parallels the SAMHD1-driven mitochondrial-to-interferon signaling axis, though it operates through a distinct RNA-sensing (rather than dNTPase/cGAS-mtDNA) mechanism within the broader interferonopathy spectrum.
DOI: 10.21203/rs.3.rs-4356120/v2

A Multi-Center Integrative Cohort Characterizing the Genetic, Clinical, and Transcriptomic Features of ACP5 Deficiency. (from Rheumatology/genetics (skeletal dysplasia and immune dysregulation))
Zhong Shiling; Ma Shuangyue; El Chazli Yasmine; Zheng Jika; Sun Xiangwei — Arthritis & rheumatology (Hoboken, N.J.) 2026
Score: 5/10 | Pathways: JAK-STAT, NF-kB-IKK, AGS-spectrum, clinical-phenotype, treatment-target

ACP5/SPENCDI is a distinct interferonopathy with overlapping type I IFN, NF-κB, and JAK-STAT signaling and JAK inhibitor treatment response, offering mechanistic and therapeutic parallels to the SAMHD1 interferonopathy spectrum despite being a different causal gene.
DOI: 10.1002/art.70279

Leveraging Mitochondria-Endoplasmic Reticulum Functional Interplay With an On-Demand Nanoparticle to Boost mtDNA-Based STING Immunotherapy. (from Oncology/nanomedicine)
Chen Han; Qu Haijing; Pan Yuqing; Cheng Wei; Wu Jie — Advanced materials (Deerfield Beach, Fla.) 2026
Score: 5/10 | Pathways: cGAS-STING, treatment-target

This paper explores mtDNA-driven cGAS-STING activation via a mitochondria-ER nanoparticle system for cancer immunotherapy, which is mechanistically relevant to the BLUE pathway's mtDNA-cGAS-STING axis but oncology-focused rather than SAMHD1-related.
DOI: 10.1002/adma.74146

CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia model. (from Hematology/gene therapy engineering)
Marone Romina; Lepore Rosalba; Paschoudi Kiriaki; Zuin Jessica; Sinopoli Alessan — bioRxiv : the preprint server for biology 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery

Uses prime editing to engineer epitope-shielded CD34+ HSPCs for toxin-free conditioning, representing a relevant myeloid/HSC gene correction delivery advance analogous to strategies that could correct SAMHD1 missense variants, though disease context (beta-thalassemia) is unrelated to interferonopathy pathways.
DOI: 10.64898/2026.07.07.736903

Base Editing Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of X-Linked Severe Combined Immunodeficiency (from Gene therapy/immunodeficiency)
S. de Ravin; Michelle Ma; Yuzhi Yin; Siyuan Liu; Andrés Zea Vera — Journal of Human Immunity 2026
Score: 5/10 | Pathways: gene-therapy-delivery

Demonstrates base-editing correction of a het/hemizygous immune gene mutation (IL2RG) in HSPCs, relevant as a translational precedent for future SAMHD1 A565T correction strategies but not mechanistically tied to the interferon-mitochondrial-NLRP3 axis.
DOI: 10.70962/pidtc2026abstract.4

🟢 Low Relevance (Score 3–4)

Potential specialty bridges — skim titles

Annual gout flare frequency as a marker of sustained cardiovascular risk: a clinical threshold for risk stratification. (from Rheumatology/Cardiology)
Tung Kuei-Ting; Chen Solomon Chih-Cheng; Lee Chun — Rheumatology (Oxford, England) 2026
Score: 4/10 | Pathways: urate-NLRP3, clinical-phenotype

This clinical epidemiology paper links gout flare frequency to cardiovascular risk via cumulative inflammatory burden, tangentially relevant to the GOLD pathway (dGTP-uric acid-MSU crystal-NLRP3 axis) but does not address SAMHD1, interferon, or mitochondrial mechanisms directly.
DOI: 10.1093/rheumatology/keag370

Approach to the patient with APS-1/APECED. (from Endocrinology)
Webb Taura; Pechacek Joseph; Lionakis Michail S — The Journal of clinical endocrinology and metabolism 2026
Score: 4/10 | Pathways: JAK-STAT, clinical-phenotype, other

APS-1/AIRE is a distinct monogenic autoimmune tolerance disorder with IFN-gamma-driven pathology and JAK inhibitor treatment rationale, offering only loose conceptual parallel (JAKi as interferonopathy therapy) but no direct SAMHD1/cGAS-STING/NLRP3 mechanistic overlap.
DOI: 10.1210/clinem/dgag282

MDA5 and the integrated stress response control sex-specific type 1 diabetes onset in NOD mice. (from Endocrinology/diabetes autoimmunity)
Van Dis Erik; DeGidio Alessandra T; Yao Lara; Winship Damion; Sidrauski Carmela — bioRxiv : the preprint server for biology 2026
Score: 4/10 | Pathways: AGS-spectrum, other

This paper links MDA5/IFIH1 and integrated stress response to autoimmune diabetes in the AGS-adjacent RNA-sensing innate immune context, offering tangential mechanistic overlap (nucleic acid sensing driving type I IFN-like pathology) but no direct SAMHD1, cGAS-STING, NLRP3, or mitochondrial dNTP connection.
DOI: 10.64898/2026.07.02.736190

Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening. (from functional genomics/gene editing technology)
Langley Jethro; Baudrier Lou; Curry Jada; Narta Kiran; Todesco Hayley M — Cell genomics 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

General-purpose eVLP/prime-editing methods advance is technically relevant to future SAMHD1 correction strategies but not targeted to immune/myeloid cells or the disease mechanism itself.
DOI: 10.1016/j.xgen.2026.101302

Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7. (from neurology/gene therapy (Alzheimer's disease))
Kim Yunkyung; Lee Gaeun; An Saemin; Park Hanseul; Kim Hongwon — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

This paper demonstrates PE7 prime editing technology for allele-specific correction (APOE4→APOE3) in neurons, offering a technical precedent for correcting heterozygous missense variants like SAMHD1 A565T, but is otherwise unrelated to interferonopathy/SAMHD1 biology or immune cell targeting.
DOI: 10.1002/advs.76658

SARS-CoV-2 ORF9b exploits mitochondrial recruitment to TOMM70 for proteasomal protection and tunes inflammatory remodeling during lung infection (from Virology/Structural Biology)
Yining Zhao; Lauriane Kergoat; Guilherme Dias de Melo; F. Larrous; Guillaume Dru — bioRxiv 2026
Score: 4/10 | Pathways: cGAS-STING, other

This paper explores SARS-CoV-2 ORF9b-mitochondrial (TOMM70) interactions and inflammatory remodeling via a Complex IV subunit substitute, touching on mitochondrial-innate immune crosstalk and interferon regulation but without direct SAMHD1, cGAS-STING, or NLRP3 pathway involvement relevant to the described syndrome.
DOI: 10.64898/2026.07.13.738231

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives (from biomedical engineering/nanomedicine)
Meijia Yang; Yiqiong Song; Ziyang Wang; Ke Chao; Lifeng Li — MedComm 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery

General review of genome editing delivery platforms with no SAMHD1-specific or immune/myeloid cell targeting focus, only tangentially relevant as background for future gene correction strategies.
DOI: 10.1002/mco2.70791

Proteomics-based characterization of apigenin-mediated anti-inflammatory effects in TNF-α-stimulated ARPE-19 cells. (from Ophthalmology/pharmacology (flavonoid anti-inflammatory research in retinal disease))
Chen Xi; Liao Meilin; Han Ruifang; Gao Juan; Lu Ping — International immunopharmacology 2026
Score: 3/10 | Pathways: NF-kB-IKK, JAK-STAT, ISG15-mitophagy

This paper studies apigenin's suppression of NF-κB/MAPK signaling and interferon-stimulated proteins (STAT1, ISG15, OAS3, IFIT3) in retinal pigment epithelial cells, touching peripheral pathway nodes (NF-κB, ISG15, IFN-related proteins) relevant to the syndrome's mechanism but with no SAMHD1, mitochondrial, or NLRP3 connection and an unrelated ophthalmologic/pharmacologic context.
DOI: 10.1016/j.intimp.2026.117048

Guiqi Baizhu prescription attenuates 5-FU-induced intestinal mucositis by targeting IKKβ to inhibit M1 macrophage polarization. (from Gastroenterology/Traditional Chinese Medicine oncology supportive care)
Zhou Yu-Cen; Li Ya-Ling; Ma Jing; Li Junjie; Si Qi — Chinese medicine 2026
Score: 3/10 | Pathways: NF-kB-IKK

Paper focuses on IKKβ/NF-κB inhibition in a traditional Chinese medicine model of chemotherapy-induced gut mucositis, only tangentially touching the NF-κB-IKK axis without connection to SAMHD1, interferonopathy, or mitochondrial mechanisms.
DOI: 10.1186/s13020-026-01406-z

Nanoengineering Systems for Gene Therapy: Mechanisms, Modalities, and Future Directions. (from nanotechnology/bioengineering)
Mais Raheem; Kumar Ayush; Ahmetaj Armand; Burgos-Crespo Gaby; Sanchez Mary Marga — International journal of molecular sciences 2026
Score: 3/10 | Pathways: gene-therapy-delivery, prime-editing

General review of nanomaterial delivery platforms for CRISPR/base/prime editing with no SAMHD1, immune cell, or mitochondrial-interferon pathway specificity.
DOI: 10.3390/ijms27135988

Intelligent metal-integrated hydrogels orchestrate pyroptosis and cGAS-STING for potentiated treatment of colorectal cancer peritoneal metastasis. (from Oncology/biomaterials drug delivery)
Zhang Lin-Zhu; Si Liang-Wei; Xu Hui; Xiong Fei; Qin Juan — 2026
Score: 3/10 | Pathways: cGAS-STING, other

Describes cGAS-STING activation via mtDNA/pyroptosis in a cancer-therapeutic (hydrogel/cobalt) context unrelated to SAMHD1 mechanism or family phenotypes, though it touches the same signaling node.
DOI: 10.1016/j.jconrel.2026.115184

Orchestrating the gut microbiota–mitochondrial–immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies (from Gynecology/Reproductive Health)
Haixia Tang; Yiting Zhang; Yanting Wang; Ze Zhou; Rong Sun — Frontiers in Reproductive Health 2026
Score: 3/10 | Pathways: cGAS-STING, NLRP3, other

This review covers gut microbiota-mitochondria-immune crosstalk (cGAS-STING/NLRP3, mtDNA, mitophagy) in gynecological disease but is not connected to SAMHD1, dNTP metabolism, or the family phenotype spectrum.
DOI: 10.3389/frph.2026.1845581


Pathway Coverage This Week

  • treatment-target: 20 papers
  • cGAS-STING: 18 papers
  • NLRP3: 11 papers
  • NF-kB-IKK: 11 papers
  • other: 6 papers
  • clinical-phenotype: 6 papers
  • gene-therapy-delivery: 6 papers
  • mito-ROS-NF-kB: 5 papers
  • prime-editing: 5 papers
  • urate-NLRP3: 3 papers
  • AGS-spectrum: 3 papers
  • JAK-STAT: 3 papers
  • nucleotide-rewiring: 2 papers
  • VDAC1: 2 papers
  • NF-kB-NLRP3-priming: 2 papers
  • mTOR-lysosomal: 2 papers
  • ISG15-mitophagy: 2 papers
  • dNTPase: 1 papers
  • mito-dNTP-transport: 1 papers
  • mito-dNTp-transport: 1 papers
  • POLG-mtDNA: 1 papers
  • IRF7-metabolic: 1 papers